

CURRICULUM VITAE

Brad H. Pollock, M.P.H., Ph.D., F.A.C.E.
Professor and Chairman
Rolkin Chair in Public Health Sciences
Department of Public Health Sciences,
Associate Dean for Public Health Sciences
School of Medicine
Medical Sciences 1C, Room 104
One Shields Avenue
University of California, Davis,
Davis, CA 95616-8500

Date of Preparation: October 26, 2021

I. GENERAL INFORMATION

A. Education:

1988 Ph.D.	Epidemiology (minor in Biostatistics)	University of California, Los Angeles, School of Public Health
1981 M.P.H.	Epidemiology	University of California, Los Angeles, School of Public Health
1979 B.S.	Biological Sciences (Molecular Biology)	University of California, Irvine

B. Postgraduate Training:

7/2019 – 9/2020	Academic Public Health Leadership Institute (APHLI) of the Association of Schools & Programs of Public Health (ASPPH)
-----------------	--

C. Academic Appointments:

7/2021 – present	Distinguished Professor	Division of Epidemiology and Division of Biostatistics, Department of Public Health Sciences, School of Medicine, University of California, Davis
7/2017 – 6/2021	Professor, Step IX.5	Division of Epidemiology and Division of Biostatistics, Department of Public Health Sciences, School of Medicine, University of California, Davis
7/2017 – present	Associate Dean for Public Health Sciences	School of Medicine, University of California, Davis

9/2015 – present	Adjunct Professor	Department of Epidemiology and Biostatistics, School of Medicine, University of Texas Health at San Antonio
9/2014 – present	Chairman	Department of Public Health Sciences, School of Medicine, University of California, Davis
9/2014 – present	Endowed Chair	Arline Miller Rolkin Chair in Public Health Sciences
9/2014 – 6/2017	Professor, Step VIII	Division of Epidemiology, Department of Public Health Sciences, School of Medicine, University of California, Davis
1/2009 – 9/2014	Endowed Chair	Henry B. Dielmann Distinguished University Chair, University of Texas Health Science Center at San Antonio
6/2006 – 9/2014	Founding Chairman	Department of Epidemiology and Biostatistics, School of Medicine, University of Texas Health Science Center at San Antonio
12/2006 – 9/2014	Professor	Department of Surgery, University of Texas Health Science Center at San Antonio
9/2006 – 9/2014	Adjunct Professor	Department of Management Sciences and Statistics, College of Business, University of Texas at San Antonio
5/2003 – 9/2014	Adjunct Professor	School of Public Health, University of Texas Health Science Center at Houston
8/2001 – 5/2006	Center Director	Center for Epidemiology and Biostatistics, University of Texas Health Science Center at San Antonio
8/2001 – 7/2011	Associate Director	Cancer Prevention and Control, Cancer and Therapy Research Center, University of Texas Health Science Center at San Antonio
8/2001 – 12/2006	Deputy Director	Children’s Cancer Research Institute, University of Texas Health Science Center at San Antonio
8/2001 – 9/2014	Professor	Department of Pediatrics, University of Texas Health Science Center at San Antonio
8/2001 – 9/2014	Professor	Department of Medicine, University of Texas Health Science Center at San Antonio

8/2001	Tenure	Department of Pediatrics, University of Texas Health Science Center at San Antonio
7/2001 – 10/2001	Professor	Department of Health Policy and Epidemiology, University of Florida College of Medicine, Gainesville, FL
3/2000 – 8/2001	Interim Chair	Department of Health Policy and Epidemiology, University of Florida College of Medicine, Gainesville, FL
9/1999 – 3/2000	Acting Chair	Department of Health Policy and Epidemiology, University of Florida College of Medicine, Gainesville, FL
10/1999 – 8/2001	Associate Director	Cancer Control, University of Florida/Shands Cancer Center, Gainesville, FL
7/1996	Tenure	Department of Health Policy and Epidemiology, University of Florida College of Medicine, Gainesville, FL
7/1994 – 6/2001	Associate Professor and Chief	Division of Epidemiology, Department of Health Policy and Epidemiology, University of Florida College of Medicine, Gainesville, FL
7/1993 – 6/1994	Associate Research Professor	Department of Pediatrics, University of Florida College of Medicine, Gainesville, FL
7/1993 – 7/2001	Affiliate Assistant Professor	Department of Statistics, College of Liberal Arts and Sciences, University of Florida, Gainesville, FL
7/1993 – 7/2001	Affiliate Assistant Professor	Department of Pathology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL
4/1988 – 6/1993	Assistant Research Professor	Division of Epidemiology and Biostatistics, Department of Pediatrics, University of Florida College of Medicine, Gainesville, FL
11/1980 – 9/1987	Research Associate	Division of Cardiology, Cedars-Sinai Medical Center, Los Angeles, CA

D. Honors and Awards:

- 2019 Society of Clinical Research Associates (SOCRA)
President's Award for Distinguished Service
- 1989 Delta Omega Honorary Public Health Society

- 1977 California State Scholarship
- 1976 University of California Alumni Scholarship
- 1975 L.A. Valley College Biology Department Scholarship
- 1975 University of California Faculty Alumni Scholarship

II. RESEARCH

A. Bibliography:

1. Books and/or Chapters:

Book Chapters

1. Michalek, J.E.; Cornell, J.E.; Pollock, B.H.: Understanding the Elements that Comprise Evidence-Based Medicine. In: Cohn S.M., Brower, S.T. (ed.) Surgery: Evidence-Based Practice: People's Medical Publishing House-USA, 2012, pp. 1000.
2. Pollock, B.H.; Tomlinson, G.E.: Preventing Cancer in Adulthood: Advice for Pediatricians. in: Pizzo, P.A.; Poplack, D.G. (eds.) Principles and Practice of Pediatric Oncology, 6th edition. Philadelphia: Lippincott Williams & Wilkins, 2010, pp. 1474
3. Pollock, B.H.: Why Evidence-Based Medicine? In: Cohn S. (ed.) Acute Care Surgery and Trauma: Evidenced-Based Practice. London, England: Informa Healthcare, 2009, pp. xvii - xx.
4. Bleyer A.; Hag-Alshiekh, M; Pollock, B.; Ries, L.: Methods. In: Bleyer, A.; O'Leary, M.; Barr, R.; Ries, L.A.G. (eds.) Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age: Including SEER Incidence and Survival: 1975–2000. National Cancer Institute, NIH Pub. No. 06-5767. Bethesda, MD, 2006, pp. 15–24.
5. Pollock, B.H.; Knudson, A.G.: Preventing Cancer in Adulthood: Advice for Pediatricians. In: Pizzo, P.A.; Poplack, D.G. (eds.) Principles and Practice of Pediatric Oncology, 5th edition. Philadelphia: Lippincott Williams & Wilkins, 2006, pp. 1617–1628.
6. Pollock, B.H.; Knudson, A.G.: Preventing Cancer in Adulthood: Advice for Pediatricians. in: Pizzo, P.A.; Poplack, D.G. (eds.) Principles and Practice of Pediatric Oncology, 4th edition. Philadelphia: Lippincott Williams & Wilkins, 2002, pp. 1553–1563.
7. Jenson, H.B.; Pollock, B.H.: Cardiac Cancer in HIV-Infected Patients. in: Lipshultz, S. (ed.) Cardiovascular Manifestations of HIV Infection. New York: Chapman & Hall, 1998, pp. 255–263.
8. Pollock, B.H.; Knudson, A.G.: Preventing Cancer in Adulthood: Advice for Pediatricians. in: Pizzo, P.A.; Poplack, D.G. (eds.) Principles and Practice of Pediatric Oncology, 3rd edition. Philadelphia: Lippincott-Raven, 1996, pp. 1421–1435.

2. Papers published:

Refereed Publications

1. Pollock, B.H.; Kilpatrick, A.M.; Eisenman, D.P.; Elton, K.L.; Rutherford, G.W.; Boden-Albala, B.M.; Souleles, D.M.; Polito, L.E.; Martin, N.K.; Byington, C.L.: Safe reopening of college campuses in Fall 2020: The University of California experience. *PloS One* (in press) doi: 10.1371/journal.pone.0258738.
2. Ciolino, J.D.; Spino, C.; Ambrosius, W.T.; Khalatbari, S.; Messinger Cayetano, S.; Lapidus, J.A.; Nietert, P.J.; Oster, R.A.; Perkins, S.M.; Pollock, B.H.; Pomann, G-M.; Price, L.L.; Rice, T.W.; Tosteson, T.D.; Lindsell, C.L.; Spratt, H.: Guidance for biostatisticians on their essential contributions to clinical and translational research protocol review. *J Clin Transl Sci.* 2021 Jul 12;5(1):e161. doi: 10.1017/cts.2021.814. PMID: 34527300.
3. Mehta, T.; Mahoney, J.; Leppin, A.L.; Stevens, K.R.; Yousefi-Nooraie, R.; Pollock, B.H.; Shelton, R.C.; Dolor, R.; Pincus, H.; Patel, S.; Moore, J.B.: Integrating dissemination and implementation sciences within CTSA to advance translational research: Implications for methods & processes, workforce development, and evaluation. *J Clin Transl Sci.* 2021 Jul 12;5(1):e151. doi: 10.1017/cts.2021.815. PMID: 34527291.
4. Siembida, E.J.; Loomans-Kropp, H.A.; Tami-Maury, I.; Freyer, D.R.; Sung, L.; Crosswell, H.E.; Pollock, B.H.; Roth, M.E.: Barriers and facilitators to adolescent and young adult cancer trial enrollment at NCORP sites. *J Natl Cancer Inst Spectrum*, 2021 Mar 22;5(3):pkab027. PMID: 34104866.
5. Mittal, N.; Langevin, A-M; Kyono, W.; Dickens, D.S.; Grimes, A.; Salsman, J.M.; Pollock, B.H.; Roth, M.: Barriers to Pediatric Oncologist Enrollment of Adolescents and Young Adults on a Cross-Network NCTN Supportive Care Cancer Clinical Trial, *J Adolesc Young Adult Oncol.* 2021 May 13. doi: 10.1089/jayao.2021.0041. PMID: 33983848.
6. Oster, R.A.; Devick, K.L.; Thurston, S.W.; Larson, J.L.; Welty, L.J.; Nietert, P.J.; Pollock, B.H.; Pomann, G-M.; Spratt, H.; Lindsell, C.J.; Enders, F.T.: Learning gaps among statistical competencies for clinical and translational science learners. *J Clin Translational Sci*, vol. 5 e12, pp. 1–11, PMID: 33948238.
7. Hanson, H.A.; Leiser, C.L.; Bandoli, G.; Pollock, B.H.; Karagas, M.R.; Armstrong, D.; Dozier, A.; Weiskopf, N.G.; Monaghan, M.; Davis, A.M.; Eckstrom, E.; Weng, C.; Tobin, J.N.; Kaskel, F.; Schleiss, M.R.; Szilagyi, P.; Dykes, C.; Cooper, D.; Barkin, S.L.: Charting the life course: emerging opportunities to advance scientific approaches using life course research. *J Clin Translational Sci*, vol. 5, pp. e9, 1-8, 2020, PMID: 33948236.
7. Abdelhadi, O.A.; Joseph, J.; Pollock, B.H.; Keegan, T.H.M.: Additional medical costs of chronic conditions among adolescent and young adult cancer survivors, *J Cancer Survivorship*, PMID: 33899161 (in press).
8. Alvarez, E.M.; Malogolowkin, M.; Hoch, J.S.; Li, Q.; Brunson, A.; Pollock, B.H.; Muffly, L.; Wun, T.; Keegan, T.H.M.: Treatment complications and survival among children and young adults with acute lymphoblastic leukemia. *JCO Oncol Pract* 2020, vol. 16, pp. e1120-e1133.

9. Eisenman, D.P.; Wiley, D.J.; Pollock, B.H.; Rutherford, G.W.; Rimoin, A.W.; Bibbins-Domingo, K.; Checkoway, H.; Fielding, J.; Waters, C.; Reingold, A.; Boden-Albala, B.; Goosby, E.; Dawson-Rose, C.: Recommendations for demonstrators, law enforcement and public health agencies for reducing SARS-CoV-2 transmission during civil protests. *Public Health Reports*, PMID: 33593123 (in press).
10. Xue, K.; Tang, L.; Shen, C-L.; Pollock, B.H.; Guerra, F.; Phillips, T. D.; Wang, J.-S.: Increase in aflatoxin exposure in two populations residing in East and West Texas, United States. *Int J Hyg Environ Health* 2021, vol. 231, 113662.
11. Cooper, D.M.; Guay-Woodford, L.; Blazar, B.R.; Bowman, S.; Byington, C.L.; Dome, J.; Forthal, D.; Konstan, M.W.; Kuppermann, N.; Liem, R.I.; Ochoa, E.R., Jr; Pollock, B.H.; Price, O.A.; Ramsey, B.W.; Ross, L.F.; Sokol, R.J.; Wright, R.J.: Re-opening schools safely: the case for collaboration, constructive disruption of pre-COVID expectations, and creative solutions. *J Pediatr* 2020, vol. 223, pp. 183-185.
12. Dickens D.S.; Roth, M.; Pollock, B.H.; Anne Marie Langevin, A. M: Understanding the barriers to pediatric oncologist engagement and accrual to clinical trials in National Cancer Institute-designated Community Oncology Research Programs JCO Oncol Practice 2020, vol. 16, pp. e1060-e1066.
13. Pollock, B.H.: What's missing in the assessment of adolescent and young adult (AYA) cancer outcomes? *J Natl Cancer Inst* 2020, vol. 112, pp. 975-976.
14. Paller, A.S.; Fölster-Holst, R.; Chen, S.C.; Diepgen, T., L.; Elmets, C.; Margolis, D.J.; Pollock, B. H.: No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis. *J Am Acad Dermatol* 2020, vol. 83, pp. 375-381.
15. Alvarez, E.; Malogolowkin, M.; Pollock, B.H.; Li, Q.; Johnston, E.; Marina, N.; Wun, T.; Thorpe, S.; Keegan, T.: Impact of location of inpatient cancer care on patients with Ewing sarcoma and osteosarcoma—a population-based study. *Pediatric Blood & Cancer*, 2021, Mar 15; pp: e28998.
16. Roth, M.E.; Unger, J.M.; O'Mara, A.M.; Lewis, M.A.; Budd, T.; Johnson, R.H.; Pollock, B.H; Freyer, D.R.: Enrollment of adolescents and young adults onto SWOG clinical trials: a comparative analysis by treatment site and era study. *Cancer Medicine* 2020, vol. 9, pp. 2146-2152.
17. Dahal, P.; Dhimal, M.; Belbase, K.; Tiwari, S.; Groopman, J.; West, K.; Pollock, B.; Pyakurel, S.; Acharya, G.; Aryal, S.; Ghimire, Y.N.; Neupane, M.; Poudel, R.; Van Ashbrouck, J.; Kunusoth, K.; De Saeger, S.; De Boevre, M.; Gharti-Chhetri, G.; Gurung, T.B.; Bradford, K.J.: Improving nutrition and immunity using toxin-minimizing dry chain and integrated pest management food technologies in low- and-middle income countries. *Lancet Global Health*, 2020, vol. 4, pp. e259-e260.
18. Dayal, P.; Chang, C.H.; Benko, W.S.; Ulmer, A.; Crossen, S.S.; Pollock, B.H.; Hoch, J.S.; Kisse, J.L.; Warner, L.; Marcin, J.P.: Appointment completion in pediatric neurology telemedicine clinics serving underserved patients, *Neurology Clin Practice*, 2019, vol. 9, pp. 314-321.
19. Phillips, C.A.; Pollock, B.H.: Big data for nutritional research in pediatric oncology: current state and framework for advancement. *J Natl Cancer Inst Monogr*, Sep 1;2019(54), pp. 127-13.
20. Dayal, P.; Chang, C.H.; Benko, W.S., Pollock, B.H.; Crossen, S.S.; Mouzoon, J.; Ulmer, A.M.; Hoch, J.S.; Warner, L.; Marcin, J.P.: Hospital utilization among children in underserved communities served by pediatric neurology telemedicine clinics. *JAMA*

Network Open, 2019, vol. 2, e199364.

21. Cartotto, R.; Taylor, S. L.; Holmes, J. H. IV; Arnoldo, B.; Peck, M.; Cochran, A.; King, B. T.; Bhavsar, D.; Tredget, E. E.; Stapelberg, F.; Friedman, B.; Mozingo, D.; Greenhalgh, D.; Pollock, B. H.; Palmieri, T. L.: Inhalation injury does not influence the amount of blood transfused to major burn patients: A secondary analysis from the Transfusion Requirement in Burn Care Evaluation (TRIBE) Study, *J Burn Care Res*, 2019, vol. 40, pp. 757-762.
22. Clark, J.M.; Marrufo, A.S.; Kozower, B.D.; Tancredi, D.J.; Nuño, M.; Cooke, D.T.; Pollock, B.H.; Romano, P.S.; Brown, L.M.: Cardiopulmonary testing prior to lung resection: what are thoracic surgeons doing? *Ann Thorac Surg*, 2019, pii: S0003-4975(19)30735-0.
23. Alvarez, E.M.; Malogolowkin, M.; Li, Q.; Brunson, A.; Pollock, B.H.; Muffly, L.; Wun, T.; Keegan, T.H.M.: Decreased early mortality in young adult patients with acute lymphoblastic leukemia treated at specialized cancer centers in California. *J Oncol Pract*, 2019, vol. 15, pp. e316-e327.
24. Marrufo, A.S.; Kozower, B.D.; Tancredi, D.J.; Nuño, M.; Cooke, D.T.; Pollock, B.H.; Romano, P.S.; Brown, L.M.: Thoracic Surgeons' Beliefs and Practices on Smoking Cessation Prior to Lung Resection, *Ann Thorac Surg*, 2018, vol. S0003-4975, pp. 31855-1.
25. Palmieri, T.L.; Holmes, J.H., IV; Arnoldo, B.; Peck, M.; Potenza, B.; Cochran, A.; King, B.T.; Dominic, W.; Cartotto, R.; Bhavsar, D.; Kemalyan, N.; Tredget, E.; Stapelberg, F.; Mozingo, D.; Friedman, B.; Sen, S.; Taylor, S.L.; Pollock, B.H.: Restrictive transfusion strategy is more effective in massive burns: results of the TRIBE multicenter prospective randomized trial. *Military Medicine*, 2019, vol.184(Supplement 1), pp. 11-15.
26. Parsons, H.M.; Penn, D.C.; Li, Q.; Cress, R.D.; Pollock, B.H.; Malogolowkin, M.H.; Wun, T. Keegan, T.H.M.: Clinical trial enrollment among adolescent and young adult (AYA) cancer patients from 2006 to 2013 in the United States: improved enrollment among uninsured and older young adults. *Pediatric Blood and Cancer*, 2019, vol. 66, p. e27426.
27. Cartotto, R.; Taylor, S.L.; Holmes, J. H., IV; Arnoldo, B.; Peck, M.; Potenza, B.; Cochran, A.; King, B. T.; Dominic, W.; Bhavsar, D.; Kemalyan, N.; Tredget, E. E.; Stapelberg, F.; Friedman, B.; Mozingo, D.; Greenhalgh, D.; Pollock, B. H.; Palmieri, T. L.: The effects of storage age of blood in massively transfused burn patients: A secondary analysis of The Randomized Transfusion Requirement in Burn Care Evaluation (TRIBE) Study, *Critical Care Medicine*, 2018, vol. 46, pp. e1097-e1104.
28. Hussain, S.S.; Huang, S-B.; Bedolla, R.G.; Rivas, P.; Basler, J.W.; Swanson, G.P.; Huan, T.H.; Narayanasamy, G.; Papanikolaou, N.; Miyamoto, H.; Yeh, I-T.; Reddick, R.L.; Pollock, B.H.; Ghosh, R.: Suppression of ribosomal protein RPS6KB1 by Nexrutine increases sensitivity of prostate tumors to radiation. *Cancer Letters*. 2018, vol. 433, pp. 232-241.
29. Minasian, L.M.; Frazier, A.L.; Sung, L.; O'Mara, A.; Kelaghan, J.; Change, K.; Krailo, M; Pollock, B.H.; Reaman, G.; Freyer, D.R.: Prevention of cisplatin-induced hearing loss in children: informing the design of future clinical trials. *Cancer Medicine*, 2018, vol. 7, pp. 2951-9.
30. Chang, C.H., F.T.; Lindsell, C.J.; Welty, L.J.; Benn, E.K.T.; Perkins, S.M.; Mayo,

- M.S.; Rahbar, M.H.; Kidwell, K.M.; Thurston, S.W.; Spratt, H.; Grambow, S.C.; Larson, J.; Carter, R.E.; Pollock, B.H.; Oster, R.A.: Statistical competencies for medical research learners: what is fundamental? *J Clinical and Translational Science*, 2017, vol. 1, pp 146-152.
31. Palmieri, T.L.; Holmes, J.H. 4th; Arnoldo. B.; Peck. M.; Potenza. B.; Cochran. A.; King. BT.; Dominic. W.; Cartotto. R.; Bhavsar. D.; Kemalyan. N.; Tredget. E.; Stapelberg. F.; Mazingo. D.; Friedman. B.; Greenhalgh. D.G.; Taylor, S.L.; Pollock, B.H. Transfusion Requirement in Burn Care Evaluation (TRIBE): a multicenter randomized prospective trial of blood transfusion in major burn injury. *Ann Surg*. 2017, vol. 266, pp. 595-602.
 32. DeRouen, M.C.; Parsons, H.M.; Kent, E.E.; Pollock, B.H.; Keegan, T.H.M.: Sociodemographic disparities in survival for adolescents and young adults with cancer differ by health insurance status. *Cancer Causes Control*. 2017. vol. 28, pp. 841-851.
 33. Dickens, D.S.; Pollock, B.H.: Medication prior authorization in pediatric hematology and oncology. *Pediatr Blood Cancer*. 2017, vol. 64(6).
 34. Ramirez, A.G.; Muñoz, E.; Parma, D.L.; Michalek, J.E.; Holden, A.E.C.; Phillips, T.D.; Pollock, B.H.: Lifestyle and clinical correlates of hepatocellular carcinoma in South Texas: a matched case-control study, *Clinical Gastroenterology and Hepatology*. 2017. vol. 15, pp. 1311-1312.
 35. Knight, K.; Chen, L.; Freyer, D.; Aplenc, R.; Bancroft, M.; Bliss, B.; Dang, H.; Gillmeister, B.; Hendershot, E.; Kraemer, D.; Lindenfeld, L.; Meza, J; Neuwelt, E.; Pollock, B.H.; Sung, L.: A group-wide, prospective study of ototoxicity assessment in children receiving cisplatin chemotherapy (ACCL05C1): A report from the Children's Oncology Group. *J Clin Oncol*, 2017, vol. 35, pp. 440-445.
 36. Freyer, D.R.; Lu, L.; Krailo, M.D.; Knight, K.; Bliss, B.; Pollock, B.H.; Ramdas, J.; Lange, B.; Van Hoff, D.; VanSoelen, M.L.; Wiernikowski, J.; Neuwelt, E.A.; Sung, L.: Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial. *Lancet Oncology*, 2016, S1470-2045(16)30625-8.
 37. Rahbar, M.H.; Dickerson, A.S.; Ahn, C.; Carter, R.E.; Hessabi, M.; Lindsell, C.J.; Nietert, P.J.; Oster, R.A.; Pollock, B.H.; Welty, L.J.: Characteristics of biostatistics, epidemiology, and research design programs in institutions with Clinical and Translational Science Awards. *Acad Med*. 2017, vol. 92, pp. 229-236.
 38. Pollock, B.H.; Elmore, S.; Romoser, A.; Tang, L.; Kang, M.S.; Xue, K.; Rodriguez, M.; Dierschke, N.A.; Hayes, H.G.; Hansen, H.A.; Guerra, F.; Wang, J.S.; Phillips, T.: Intervention trial with calcium montmorillonite clay in a south Texas population exposed to aflatoxin. *Food Addit Contam Part A Chem Anal Control Expo Risk Assess*. 2016, vol. 33, pp. 1346-54.
 39. Mette, L.A.; Pulido Saldivar, A.M.; Poullard, N.E.; Torres, I.C.; Seth, S.G.; Pollock, B.H.; Tomlinson, G.E.: Reaching high-risk underserved individuals for cancer genetic counseling by video-teleconferencing. *J Community Support Onc*, 2016, vol. 14, pp. 1162-168.
 40. Roth, M.E.; O'Mara, A.M.; Seibel, N.L.; Dickens, D.S.; Langevin, A-M; Pollock, B.H.; Freyer, D.R.: Low adolescent/young adult enrollment onto cancer trials: Insights from the Community Clinical Oncology Program. *J Oncology Practice*, 2016, vol. 12, pp. e388-95.

41. Keegan T.H.; Ries, L.A.; Barr, R.D.; Geiger, A.M.; Dahlke, D.V.; Pollock, B.H.; Bleyer, A.: Comparison of cancer survival trends in the United States of adolescents and young adults with those in children and older adults, *Cancer*, 2016, vol. 122, pp. 1009-16.
42. Barr, R.D.; Ries, L.A.G.; Lewis D.R.; Harlan L.C.; Keegan T.H.; Pollock, B.H.; Bleyer, W. A.: Incidence and incidence trends of the most frequent cancers in adolescent and young adult Americans, including “non-malignant” tumors, *Cancer*, 2016, vol. 122, pp. 1000-8.
43. Ha, C.S.; Michalek, J.; Elledge, R.; Kelly, K.R.; Ganapathy, S.; Su, H., Jenkins, C.A.; Argiris, A.; Swords, R.; Eng, T.Y.; Karnad, A.; Crownover, R.L.; Swanson, G.P.; Goros, M.; Pollock, B.H.; Yuan, Z-M: p53-based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study, *Molecular Oncology*, 2016, vol. 10, pp. 148-56.
44. Gelfond, J.A.L.; Klugman, C.M.; Welty, L.J.; Heitman, E.; Loudon, C.; Pollock, B.H.: How to tell the truth with statistics: the case for accountable data analyses in team-based science. *J Transl Med Epidemiol*. 2014, vol. 2, pp. 1025-1030.
45. Al-Rajabi, R.; Patel, S.; Ketchum, N.S.; Jaime, N.A.; Lu, T.W.; Pollock, B.H.; Mahalingam, D.: Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction. *J Gastrointest Oncol*. 2015, vol. 6, pp. 259-67.
46. Mazumdar, M.; Messinger, S.; Ash, A.; Finkelstein, D.M.; Fox, E.; Goldberg, J.D.; Kopras, E.; Lindsell, C.; Morton, S.; Pollock, B.H.; Rahbar, M.H.; Shara, N.; Spratt, H.; Welty, L.J.; Parker, R.A.; and the Biostatistics, Epidemiology, and Research Design (BERD) Key Function Committee of the Clinical and Translational Science (CTSA) Consortium: Evaluating scientists collaborating in team based research: a case study of biostatisticians involved in clinical and translational research teams, *Clinical Translational Sci*, 2015, vol. 90, pp. 1302-8.
47. Oster, R.A.; Lindsell, C.J.; Welty, L.J.; Mazumdar, M.; Thurston, S.W.; Rahbar, M.H.; Carter, R.E.; , Pollock, B.H.; Cucchiara, A.J.; Kopras, K.J. Jovanovic, B.D.; Enders, F.T.: Assessing statistical competencies in clinical and translational science education: one size does not fit all, *Clinical Translational Sci*, 2015, vol. 8, pp. 32-42.
48. Trevino, M.; Padalecki, S.; Karnad, A.; Parra, A.; Weitman, S.; Nashawati, M.; Pollock, B.H.; Ramirez, A.; Thompson, I.M. The development of a minority recruitment plan for cancer clinical trials. *J Community Med Health Educ*. 2013, vol. 3, pp. 1000230.
49. Chalela, P.; Suarez, L.; Muñoz, E.; Gallion, K.J.; Pollock, B.H.; Weitman, S.D.; Karnad, A.; Ramirez, A.G. Promoting factors and barriers to participation in early phase clinical trials: patients’ perspectives. *J Community Med Health Educ*. 2014, vol. 4, pp. 1000281-.
50. Patel, S.R.; Karnad, A.B.; Ketchum, N.S.; Pollock, B.H.; Sarantopoulos, J.; Weitman, S.; Mahalingam, D. Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials. *J Gastrointest Oncol*. 2014, vol. 5, pp. 99-103.
51. Chen-Pin; W; Javier; H.; Lorenzo, C.; Downs, J.R.; Thompson, I.M.; Pollock, B.; Lehman, D.: Statins and finasteride use differentially modify the impact of metformin on prostate cancer incidence in men with type 2 diabetes. *Ann Transl Med Epidemiol*. 2014, vol. 1, pp. 1004-1020.

52. Sim, I.; Tu, S.W.; Carini, S.; Lehmann, H.P.; Pollock, B.H.; Peleg, M.; Wittkowski, K.M.: The Ontology of Clinical Research (OCRe): an informatics foundation for the science of clinical research. *Journal of Biomedical Informatics*, 2013, S1532–0464(13)00179–2.
53. Ramirez, A.G.; Chalela, P.; Suarez, L.; Muñoz, E., Pollock, B.H.; Weitman, S.D.; Gallion, K.J.: Early phase clinical trials: referral barriers and promoters among physicians. *J Community Med Health Educ*. 2012, vol. 24, pp. 1–18.
54. Andrews, C.P.; Ratner, P.H.; Ehler, B.R.; Brooks, E.G.; Pollock, B.H.; Ramirez, D.A.; Jacobs, R.L.: The Mountain Cedar Model in clinical trials of seasonal allergic rhinoconjunctivitis. *Annals of Allergy, Asthma & Immunology*, 2013, vol. 111, pp. 9–13.
55. Welty, L.J., Carter, R.E.; Finkelstein, D.; Harrell Jr., F.E.; Lindsell, C.J.; Macaluso, M.; Mazumdar, M.; Nietert, P.J.; Oster, R.A.; Pollock, B.H.; Roberson, P.K.; Ware, J.H.: Strategies for developing biostatistics resources in an academic health center. *Academic Medicine*. 2013, vol. 88, pp. 454–460.
56. Sim, I.; Carini, S.; Tu, S.W.; Detwiler, L.T.; Brinkley, J.; Mollah, S.A.; Burke, K.; Lehmann, H.P.; Chakraborty, S.; Wittkowski, K.M.; Pollock, B.H.; Johnson, T.M.; Huser, V.; for the Human Studies Database Project: Ontology-based federated data access to human studies information. *American Medical Informatics Assoc. Annual Symposium Proceedings*. 2012, vol. 2012, pp. 856–865.
57. Schüz, J.; Grell, K.; Kinsey, S.; Linet, M.S.; Link, M.P.; Mezei, G.; Pollock, B.H.; Roman, E.; Zhang, Y.; McBride, M.M.; Johansen, C.; Spix, C.; Hagihara, J.; Saito, A.; Simpson, J.; Robison, L.L.; Dockerty, J.; Feychting, M.; Kheifets, L.; Frederiksen, K.: Extremely low–frequency magnetic fields and survival of childhood leukemia: an international follow up study. *Blood Cancer Journal*, 2012, vol. 2, pp. e98–102.
58. Joyce, M.J.; Pollock, B.H.; Devidas, M.; Buchanan, G.R.; Camitta, B.: Chemotherapy for initial induction failures in childhood acute lymphoblastic leukemia: A Children's Oncology Group Study (POG 8764). *J Pediatr Hematol Oncol*, 2013, vol. 35, pp. 32–35.
59. Sellers, R.V.; Salazar, R.; Martinez, C., Jr.; Gelfond, S.D.; Deuter, M.; Hayes, H.G.; Ketchum, N.; Pollock, B.H.: Difficult encounters with psychiatric patients: A South Texas Psychiatry Practice–Based Research Network (PBRN) Study. *J Am Board Family Med*, 2012, vol. 25, pp. 669–75.
60. Gelfond, J.A.L.; Heitman, E.; Pollock, B.H.; Klugman, C.: Power, ethics, and obligation. *Statistics in Medicine*, 2012, vol. 31, pp. 4140–1.
61. Firoz, B; Henning, J.S.; Zarzabal, L.A.; Pollock, B.H.: Toxic epidermal necrolysis: five years of treatment experience from a burn unit. *J Am Acad Dermatol*, 2012 vol. 67, pp. 630–5.
62. Gelfond, J.A.L.; Heitman, E.; Pollock, B.H.; Klugman, C.: Principles for the ethical analysis of clinical and translational research. *Statistics in Medicine*, 2011, vol. 30, pp. 2785–92.
63. Liang, Y.; Ankerst, D.P.; Ketchum, N.S.; Leach, R.J.; Thompson, I.M.; Pollock, B.H.: Population–based screening for prostate cancer: improved outcomes in African American men. *Annals Urology*, http://slm-respiratory.com/uploads/media/Population-Based_Screening_for_Prostate_Cancer_Improved_Outcomes_in_African_American

Men.pdf.

64. Pandya, D.M.; Patel, S.; Ketchum, N.S.; Pollock, B.H.; Padmanabhan, S.: A comparison of races and leukemia subtypes among patients in different cancer survivorship phases. *Clin Lymphoma Myeloma Leuk*, 2011, vol. 11 Suppl 1, pp. S114–8.
65. Kurtzberg, J.; Asselin, B.; Bernstein, M.; Buchanan, G.R.; Pollock, B.H.; Camitta, B.M.: Polyethylene glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866). *J Pediatr Hematol Oncol*, 2011, vol. 33, pp. 610–6.
66. Forcade, N.A.; Parchman, M.L.; Jorgensen, J.H.; Du, L.C.; Nyren, N.R.; Treviño, L.B.; Peña, J.; Mann, M.W.; Muñoz, A.; Treviño, S.B.; Mortensen, E.M.; Wickes, B.L.; Pollock, B.H.; Frei, C.R.: Prevalence, severity, and treatment of CA-MRSA skin and soft tissue infections in 10 medical clinics in Texas: A STARNet Study. *J Am Board of Family Medicine*, 2011, vol. 24, pp. 543–50.
67. Beuten, J.; Gelfond, J.A.; Piwkhram, D.; Pollock, B.H.; Winick, N.J.; Collier, A., 3rd; Tomlinson, G.E.: Candidate gene association analysis of acute lymphoblastic leukemia identifies new susceptibility locus at 11p15 (LMO1). *Carcinogenesis*, 2011, vol. 32, pp. 1349–53.
68. Swinney, R.M.; Beuten, J.; Collier, A., 3rd; Chen, T.; Winick, N.; Pollock, B.H.; Tomlinson, G.E.: Polymorphisms in CYP1A1 and ethnic-specific susceptibility to acute lymphoblastic leukemia in children. *Cancer Epidemiol Biomarkers Prev*, 2011, vol. 20, pp. 1537–42.
69. Holcomb, J.B.; Weiskopf, R.; Champion, H.; Gould, S.A.; Sauer, R.M.; Brasel, K.; Bochicchio, G.; Bulger, E.; Cotton, B.A.; Davis, D.; Dutton, R.; Hauser, C.J.; Hess, J.R.; Hides, G.A.; Knudson, P.; Mackenzie, E.; McGinnis, R.L.; Michalek, J.; Moore, F.A.; Omert, L.; Pollock, B.H.; Tortella, B.; Sugarman, J.; Schreiber, M.A.; Wade, C.E.: Challenges to effective research in acute trauma resuscitation: consent and endpoint. *Shock*, 2011, vol. 35, pp. 107–13.
70. Piwkhram, D.; Gelfond, J.A.; Rerkamnuaychoke, B.; Pakakasama, S.; Rebel, V.I.; Pollock, B.H.; Winick, N.; Collier, A. 3rd.; Tomlinson, G.; Beuten, J.: Multi-locus association of genetic variants in MLL, CREBBP, EP300 and TOP2A with childhood acute lymphoblastic leukemia in Hispanics from Texas. *Cancer Epidemiol Biomarkers Prev*, 2011, vol. 20, pp. 1204–12.
71. Ankerst, D.P.; Pollock, B.H.; Liang, Y.; Dizdarevic, N.; Kyrylenko, S.; Boeck, A.; Thompson, I.M.; Leach, R.: Trends and co-trends of Prostate-Specific Antigen and body mass index in a screened population. *Urology*. 2011, vol. 78, pp. 10–6.
72. Guadalupe, M.; Pollock, B.H.; Westbrook, S.; Redding, S.; Bullock, D.; Anstead, G.; Agan, B.K.; Marconi, V.C.; Barbieri, S.; Sankar, V.; Rebeles, J.; Flahive, Y.; Schoolfield, J.; Wang, L.; Lei, X.; Dow, D.; Yeh, C.K.; Dang, H.; Infante, A.J.; Gao, S.J.: Risk factors influencing antibody responses to Kaposi's Sarcoma-Associated Herpesvirus latent and lytic antigens in patients under antiretroviral therapy. *J Acquir Immune Defic Syndr*, 2011, vol. 56, pp. 83–90.
73. Vriens, M.R.; Moses, W.; Weng, J., Peng, M.; Griffin, A.; Bleyer, A.; Pollock, B.H.; Indelicato, D.J.; Hwang, J.; Kebebew, E.: Clinical and molecular features of papillary thyroid cancer in adolescents and young adults. *Cancer*, 2011, vol. 117, pp. 259–67.

74. Sim, I.; Carini, S.; Tu, S.; Wynden, R.; Pollock, B.H.; Mollah, S.A.; Gabriel, D.; Hagler, H.K.; Scheuermann, R.H.; Lehmann, H.P.; Wittkowski, K.M.; Nahm, M.; Bakken, S.: The Human Studies Database Project: Federating human studies design data using the ontology of clinical research. *American Medical Informatics Association Summits Transl Sci Proc.*, 2010, vol. 1; pp. 51–5.
75. Collins, L.; Zarzabal, L.A.; Nayiager, T.; Pollock, B.H.; Barr, R.D.: Growth in children with acute lymphoblastic leukemia during treatment. *J Ped Hematology/Oncology*, 2010, vol. 32, pp. e304–e307.
76. Carini, S.; Pollock, B.H.; Lehmann, H.P.; Bakken, S.; Barbour, E.M.; Gabriel, D.; Hagler, H.K.; Harper, C.R.; Mollah, S.A.; Nahm, M.; Nguyen, H.H.; Scheuermann, R.H.; Sim, I.: Development and evaluation of a study design typology for human research. *Proceedings of the 2009 American Medical Informatics Association Annual Symposium*, 2009.
77. Papagerakis, S.; Shabana, A-H; Pollock, B.; Papagerakis, P.; Depondt, J.; Berdal, A.: Altered desmoplakin expression at transcriptional and protein levels provides prognostic. *Human Pathology*, 2009, vol. 40, pp. 1320–9.
78. Pollock, B.H.: Cheaper, Faster, Better: Chasing the elusive clinical trial endpoint. *J Clin Oncology*, 2009, vol. 27, pp. 2747–8.
79. Goel, R.; Olshan, A.F.; Ross, J.A.; Breslow, N.E.; Pollock, B.H.: Maternal exposure to medical radiation and Wilms tumor in the offspring: a report from the Children’s Oncology Group. *Cancer Causes Control*, 2009, vol. 20, pp. 957–63.
80. Baillargeon, J.; Snyder, N.; Soloway, R.D.; Paar, D.; Baillargeon, G.; Spaulding, A.C.; Pollock, B.H.; Arcari, C.M.; Williams, B.A.; Raimer, B.G.: Hepatocellular carcinoma prevalence and mortality in a male state prison population. *Public Health Reports*, 2009, vol. 124, pp. 120–6.
81. Rubin, D.; Dodd, M.; Desai, N.; Pollock, B.; Graham-Pole, J.: Spirituality in well and ill adolescents and their parents: the use of two assessment scales. *Pediatr Nurs*, 2009, vol. 35, pp. 37-42.
82. Ankerst, D.P.; Miyamoto, R.; Nair, P.V.; Pollock, B.H.; Thompson, I.M.; Parekh, D.: Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population. *J Urology*, 2009, vol. 181, pp 2071–5.
83. Baillargeon, J.; Giordano, T.P.; Rich, J.D.; Wu, Z.H.; Wells, K.; Pollock, B.H.; Paar, D.P.: Accessing antiretroviral medication following release from prison, *JAMA*, 2009, *JAMA*, vol. 301, pp. 848–57.
84. Ankerst, D.P.; Groskopf, J.; Day, J.R.; Blasé, A.; Rittenhouse, H.; Pollock, B.H.; Tangen, C.; Parekh, D.; Leach, R.J.; Thompson, I.: Predicting prostate cancer risk through incorporation of Prostate Cancer Gene 3. *J Urology*, 2008, vol. 180, pp. 1303–8.
85. Kato, P.M.; Cole, S.W.; Bradlyn, A.S.; Pollock, B.H.: A video game improves behavioral outcomes in adolescents and young adults with cancer: a randomized trial. *Pediatrics*, 2008, vol. 122, pp. e305–17.
86. Brawley, O.W.; Cornelius, L.J.; Edwards, L.R.; Gamble, V.N.; Green, B.L.; Inturrisi, C.; Eyberg, A.H.; Laraque, D.; Mendez, M.; Montoya, C.J.; Pollock, B.H.; Robinson, L.; Scholnik, A.P.; Schori, M.: National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. *Ann Intern Med*.

2008, vol. 148, pp. 932–8.

87. Baillargeon, J.; Thomas, C.R.; Williams, B.; Begley, C.E.; Sharma, S.; Pollock, B.H.; Murray, O.J.; Pulvino, J.S.; Raimer, B.: Medical emergency department utilization patterns among uninsured patients with psychiatric disorders. *Psychiatr Serv.* 2008, vol. 59, pp. 808–11.
88. Brawley, O.W.; Cornelius, L.J.; Edwards, L.R.; Gamble, V.N.; Green, B.L.; Inturrisi, C.E.; James, A.H.; Laraque, D.; Mendez, M.H.; Montoya, C.J.; Pollock, B.H.; Robinson, L.; Scholnik, A.P.; Schori, M.: NIH Consensus Development Statement on Hydroxyurea Treatment for Sickle Cell Disease. *NIH Consens State Sci Statements.* 2008, vol. 25, pp. 1–30.
89. Pollock, B.H.; Birch, J.M.: Registration and classification of adolescent and young adult cancer cases. *Pediatric Blood & Cancer*, 2008, vol. 50, pp. 1090–1093.
90. Pollock, B.H.: Where adolescents and young adults with cancer receive their care: does it matter? *J Clin Oncol*, vol. 25, 2007, pp. 4522–3.
91. Reed, A.; Ankerst, D.P.; Pollock, B.H.; Thompson, I.M.; Parekh, D.J.: Current age- and race-adjusted PSA threshold values delay diagnosis of high grade prostate cancer. *J Urology*, vol. 178, 2007, pp. 1929–32.
92. Baillargeon, J.; Langevin, A.M.; Lewis, M.; Estrada, J.; Grady, J.J.; Mullins, J.; Pitney, A.; Pollock, B.H.: Demographic correlates of body size changes in children undergoing treatment for acute lymphoblastic leukemia. *Pediatr Blood Cancer*, vol. 49, 2007, pp. 793–6.
93. Doolittle, N.D.; Peereboom, P.M.; Christoforidis, G.A.; Hall, W.A.; Palmieri, D.; Brock, P.R.; Campbell, K.; Dickey, D.T.; Muldoon, L.L.; O’Neill, B.P.; Peterson, D.R.; Pollock, B.; Soussain, C.; Smith, Q.; Tyson, R.M.; Neuwelt, E.A.: Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: Report of the Eleventh Annual Blood–Brain Barrier Consortium Meeting. *Journal of Neuro-Oncology* (in press).
94. Foliart, D.E.; Mezei, G.; Iriye, R.; Silva, J.M.; Ebi, K.L.; Kheifets, L.; Link, M.P.; Kavet, R.; Pollock, B.H.: Magnetic field exposure and prognostic factors in childhood leukemia. *Bioelectromagnetics*. vol. 28, 2007, pp. 69–71.
95. Cooney, M.A.; Daniels, J.L.; Ross, J.A.; Breslow, N.E.; Pollock, B.H.; Olshan, A.F.: Household pesticides and the risk of Wilms tumor. *Environmental Health Perspectives*, vol. 115, 2007, pp. 134–37.
96. Washburn, W.K.; Pollock, B.H.; Nichols, L.; Speeg, K.V.; Half, G.: Impact of recipient MELD score on resource utilization. *Am J Transplant*, vol. 6, 2006, pp. 2449–54.
97. Baillargeon, J.; Platz, E.A.; Rose, D.P.; Pollock, B.H.; Ankerst, D.P.; Haffner, S.; Higgins, B.; Lokshin, A.; Troyer, D.; Hernandez, J.; Lynch, S.; Leach, R.J.; Thompson, I.M.: Obesity; adipokines; and prostate cancer in a prospective population-based study. *Cancer Epidemiol Biomarkers Prevention*, vol. 15, 2006, pp. 1331–5.
98. Baillargeon, J.; Langevin, A.–M.; Lewis, M.; Wall, D.; Mullins, J.; Pitney, A.; Ma, J.Z.; Chisholm, G.B.; Pollock, B.H.: Obesity and survival in a cohort of predominantly Hispanic children with acute lymphoblastic leukemia. *J Pediatr Hematol Oncol*, vol. 28, 2006, pp. 575–8.

99. Bahar, R.; Hartmann, C.H.; Rodríguez, K.A.; Denny, A.D.; Busuttill, R.A.; Dollé, M.E.T.; Calder, R.B.; Chisholm, G.B.; Pollock, B.H.; Klein, C.A.; Vijg, J.: Increased cell-to-cell variation in gene expression in aging mouse heart. *Nature*, vol. 441, 2006, pp. 1011–4.
100. Reyes; M.; Steinhilper, M.; Alvarez, J.; Escobedo, D.; Pearce, J.; Valvano, J.; Pollock, B.; Wei, C-L.; Kottam, A.; Altman, D.; Lee, S.; Bailey, S.; Thomsen, S.; Freeman, G.; Feldman, M.: Impact of physiologic variables and genetic background on myocardial frequency-resistivity relations in the intact beating murine heart. *American Journal of Physiology—Heart and Circulatory Physiology*, vol. 291, 2006, pp. H1659–69.
101. Bandyopadhyay, A.; Agyin, J.K.; Wang, L.; Tang, Y.; Lei, X.; Story, B.; Cornell, J.E.; Pollock, B.H.; Mundy, G.R.; Sun, L-Z.: Inhibition of breast cancer metastasis to bone by a TGF β type I receptor kinase inhibitor. *Cancer Research*, vol. 66, 2006, pp. 6714–21.
102. Shaughnessy, P.J.; Bachier, C.; Lemaistre, C.F.; Akay, C.; Pollock, B.H.; Gazitt, Y.: Granulocyte colony–stimulating factor mobilizes more dendritic cell subsets than granulocyte–macrophage colony-stimulating factor with no polarization of dendritic cell subsets in normal donors. *Stem Cells*. vol. 24, 2006, pp. 1789–97.
103. Bluhm, E.C.; Daniels, J.; Pollock, B.H.; Olshan A.F.: Maternal use of recreational drugs and neuroblastoma in offspring: a report from the Children’s Oncology Group (United States). *Cancer Causes Control*. vol. 17, 2006, pp. 663–9.
104. Stefanidis, D.; Pollock, B.H.; Miranda, J.; Wong, A.; Sharkey, F.E.; Rousseau, D.L.; Thomas, C.R., Jr.; Kahlenberg, M.S.: Colorectal cancer in Hispanics: a population at risk for earlier onset, advanced disease, and decreased survival. *Am J Clin Oncology*. Vol. 29, 2006, pp. 123–6.
105. Foliart, D.E.; Pollock, B.H.; Mezei, G.; Iriye, R.; Silva, J.M.; Ebi, K.L.; Kheifets, L.; Link, M.P.; Kavet, R.: Magnetic field exposure and long-term survival among children with leukaemia. *Br J Cancer*. vol. 94, 2006, pp. 161–4.
106. Grabinski, J.L.; Smith, L.S.; Chisholm, G.B.; Drengler, R.; Rodriguez, G.I.; Lang, A.S.; Kalter, S.P.; Garner, A.M.; Fichtel, L.M.; Hollsten, J.; Pollock, B.H.; Kuhn, J.G.: Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy. *Breast Cancer Res Treat*. Vol. 95, 2005 pp. 13–16.
107. Baillargeon J, Langevin AM, Lewis M, Thomas PJ, Mullins J, Dugan J, Pollock BH.: L-asparaginase as a marker of chemotherapy dose modification in children with acute lymphoblastic leukemia. *Cancer*, vol. 104, 2005 pp. 2858–61.
108. Cavanaugh, S.X.; Fuller, C.D.; Kupelian, P.A.; Reddy, C.; Bradshaw, P.; Pollock, B.H.; Fuss, M.: Time and PSA threshold model prognosticates long–term overall and disease-specific survival in prostate cancer patients as early as 3 months after external beam radiation therapy. *Prostate Cancer Prostatic Dis.*, vol. 8, 2005, pp. 353–8.
109. Hirschman, B.A.; Pollock, B.H.; Tomlinson, G.E.: The spectrum of APC mutations in children with hepatoblastoma from Familial Adenomatous Polyposis kindreds. *J Pediatr*. vol. 147, 2005, pp. 263–6.
110. Learn, P.A.; Yeh, I.T.; McNutt, M.; Chisholm, G.B.; Pollock, B.H.; Rousseau, D.L., Jr.; Sharkey, F.E.; Cruz, A.B.; Kahlenberg, M.S. HER–2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma. *Cancer*, vol. 103, 2005; pp. 2252–60.

111. Baillargeon, J.; Langevin, A.M.; Mullins, J.; Ferry, R.J., Jr.; Deangulo, G.; Thomas, P.J.; Estrada, J.; Pitney, A.; Pollock, B.H.: Transient hyperglycemia in Hispanic children with acute lymphoblastic leukemia. *Pediatr Blood Cancer*, vol. 44, 2005, pp. 1–4.
112. Baillargeon, J.; Langevin, A.M.; Lewis, M.; Grady, J.J.; Thomas, P.J.; Mullins, J.; Estrada, J.; Pitney, A.; Sacks, N.; Pollock, B.H.: Therapy-related changes in body size in Hispanic children with acute lymphoblastic leukemia. *Cancer*, vol. 103, 2005, pp. 1725–9.
113. Baillargeon, J.G.; Pollock, B.H.; Kristal, A.; Bradshaw, P.; Hernandez, J.; Basler, J.; Higgins, B.; Lynch, S.; Rozanski, T.; Troyer, D.; Thompson, I.: The association of body mass index and prostate specific antigen in a population-based study. *Cancer*, vol. 103, 2005, pp. 1092–5.
114. Cavanaugh, S.X.; Kupelian, P.A.; Fuller, C.D.; Reddy, C; Bradshaw P.; Pollock, B.H.; Fuss, F.: Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy: prognostic value of a time-and-PSA threshold model. *Cancer*, vol. 101, 2004, pp. 96–105.
115. Baillargeon, J.; Pollock, B.H.; Leach, C.T.; Gao, S.J.: The association of neoplasms and HIV infection in the correctional setting. *International Journal of STD & AIDS*, vol. 15, 2004, pp. 348–51.
116. Pakakasama, S.; Chen, T.T.; Frawley, W.; Muller, C.Y.; Douglass, E.C.; Lee, R.; Pollock, B.H.; Tomlinson, G.E.: CCND1 polymorphism and age of onset of hepatoblastoma. *Oncogene*, vol. 10, 2004, pp. 4789–92.
117. Baillargeon, J.; Kelley, M.F.; Leach, C.T.; Baillargeon, G.; Pollock, B.H.: Methicillin-resistant *Staphylococcus aureus* infection in the Texas prison system. *Clin Infect Dis*, vol. 38, 2004, pp. e92–5.
118. Menegaux, F.; Olshan, A.F.; Neglia, J.P.; Pollock, B.H.; Bondy, M.L.: Day care, childhood infections, and risk of neuroblastoma. *Am J Epidemiol*, vol. 159, 2004, pp. 843–51.
119. Thompson, I.M.; Leach, R.; Troyer, D.; Pollock, B.H.; Naylor, S.; Higgins, B.: Relationship of body mass index and prostate specific antigen in a population-based study. *Urol Oncol*, vol. 22, 2004, pp. 127–31.
120. Cook, M.N.; Olshan, A.F.; Guess, H.A.; Savitz, D.A.; Poole, C.; Blatt, J.; Bondy, M.L.; Pollock BH: Maternal medication use and neuroblastoma in offspring. *American Journal of Epidemiology*, vol. 159, 2004, pp. 721–31.
121. Thompson, I.M.; Albanes, D.; Basler, J.W.; Crawford, E.D.; Denis, L.J.; Djavan, B.; Fleshner, N.; Johnson-Pais, T.L.; Klein, E.A.; Kristal, A.R.; Lucia, M.S.; Parnes, H.L.; Piazza, G.A.; Platz, E.A.; Pollock, B.H.; Price, D.K.; Reichardt, J.K.; Tangen, C.M.; Tolcher, A.W.; McMann, M.C.: First International Conference on Chemoprevention of Prostate Cancer. *Journal of Urology*, vol. 171, 2004.
122. Thompson, I.M.; Basler, J.; Hensley, D.; von Merveldt, D.; Jenkins, C.A.; Higgins, B.; Leach, R.; Troyer, D.; Pollock, B.: Prostate cancer prevention: what do we know now, and when will we know more? *Clinical Prostate Cancer*, vol. 1, 2003, pp. 215–220.
123. Pollock, B.H.; Jenson, H.B.; Leach, C.T.; McClain, K.L.; Hutchison, R.E.; Garzarella, L.; Joshi, V.V.; Parmley, R.T.; Murphy, S.B.: Risk factors for pediatric human immunodeficiency virus-related malignancy. *JAMA*, vol. 289, 2003, pp. 2393–9.

124. Leach, R.; Pollock, B.H.; Basler, J.; Troyer, D.; Naylor, S.; Thompson, I.M.: Chemoprevention of prostate cancer: Focus on key opportunities and clinical trials. *Urol Clin N Am*, vol. 30, 2003, pp. 227–237.
125. Thomas, C.T.; Bradshaw, P.T.; Pollock, B.H.; Montie, J.E.; Taylor, J.M.; Thames, H.D.; McLaughlin, P.W.; DeBiase, D.A.; Hussey, D.H.; Wahl, R.L.: Indium-111-capromab pentetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. *J Clinical Oncol*, vol. 21, 2003, pp. 1715–21.
126. Thompson, I.; Leach, R.J.; Pollock, B.H.; Naylor, S.L.: Prostate Cancer and Prostate-Specific Antigen: The more we know, the less we understand. Editorial, *J National Cancer Institute*, vol. 95, 2003, pp. 1027–8.
127. Mehta, P.; Pollock, B.H.; Nugent M.; Horowitz, M.; Wingard, J.R.: Access to stem cell transplantation: do women fare as well as men? *Am J Hematol*, vol. 72, 2003, pp. 99–102.
128. Pillai, M.R.; Sreevidya, S.; Pollock, B.H.; Jayaprakash, P.G.; Herman, B.: Human papillomavirus type 16 E6 and E7 gene variations in Indian cervical cancer. *Gynecol Oncol*, vol. 87, 2002, pp. 268–73.
129. Pillai, M.R.; Sreevidya, S.; Pollock, B.H.; Jayaprakash, P.G.; Herman, B.: Polymorphism at codon 72 of p53, human papillomavirus, and cervical cancer in South India. *J Cancer Res Clin Oncol*, vol. 128, 2002, pp. 627–31.
130. Zumberg, M.S.; del Rosario, M.L.; Nejame, C.F.; Pollock, B.H.; Garzarella, L.; Kao, K.J.; Lottenberg, R.; Wingard, J.R.: A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger. *Biol Blood Marrow Transplant*, vol. 8, 2002, pp. 569–76.
131. Balic, I.; Graham, S.T.; Troyer, D.A.; Higgins, B.A.; Pollock, B.H.; Johnson-Pais, T.L.; Thompson, I.M.; Leach, R.J.: Androgen receptor length polymorphism associated with prostate cancer risk in Hispanic men. *Journal of Urology*, vol. 168, 2002, pp. 2245–48.
132. Olshan, A.F.; Smith, J.C.; Bondy, M.L.; Neglia, J.P.; Pollock, B.H.: Maternal vitamin use and reduced risk of neuroblastoma. *Epidemiology*. vol. 13, 2002, pp. 575–80.
133. Daniels, J.L.; Olshan, A.F.; Pollock, B.H.; Shah, N.R.; Stram, D.O.: Breast-feeding and neuroblastoma, USA and Canada. *Cancer Causes Control*. vol. 13, 2002, pp. 401–5.
134. Ogden, A.K.; Pollock, B.H.; Bernstein, M.L.; Camitta, B.; Buchanan, G.R.: Intermediate dose-methotrexate and intravenous 6-mercaptopurine chemotherapy for children with acute lymphoblastic leukemia who failed initial induction therapy. *J Ped Hematology/Oncology*, vol. 24, 2002, pp. 182–7.
135. Leach, C.T.; Pollock, B.H.; McClain, K.L.; Parmley, R.T.; Murphy, S.B.; Jenson, H.B.: Human herpesvirus 6 (HHV-6) and cytomegalovirus (CMV) infections in children with acquired immunodeficiency syndrome (AIDS) and cancer. *Ped Infectious Disease J*, vol. 21, 2002, pp. 125–32.
136. Minn, A.Y.; Pollock, B.H.; Garzarella, L.; Dahl, G.V.; Kun, L.E.; Ducore, J.M.; Shibata, A.; Kepner, J.; Fisher, P.G.: Surveillance neuroimaging to detect relapse in childhood brain tumors: a Pediatric Oncology Group study. *J Clin Oncology*, vol. 21, 2001, pp. 4135–40.

137. De Roos, A.C.; Teschke, K.; Savitz, D.A.; Poole, C.; Grufferman, S.; Pollock, B.H.; Olshan, A.F.: Parental occupational exposures to electromagnetic fields and radiation and the incidence of neuroblastoma in offspring. *Am J Epidemiology*, vol. 12, 2001, pp. 508–17.
138. Hamrick, S.E.G.; Olshan, A.F.; Neglia, J.P.; Pollock, B.H.: Association of pregnancy history and birth characteristics with neuroblastoma: a report from the Children’s Cancer Group and the Pediatric Oncology Group. *Paediatric & Perinatal Epidemiology*, vol. 15, 2001, pp. 328–37.
139. De Roos, A.J.; Olshan, A.F.; Teschke, K.; Poole, C.; Savitz, D.A.; Blatt, J.; Bondy, M.L.; Pollock B.H.: Parental occupational exposures to chemicals and incidence of neuroblastoma in offspring. *Am J Epidemiol.* vol. 154, 2001, pp. 106–14.
140. Khan, S.A.; Gaa, B.; Pollock, B.H.; Shea, B.; Reddy, V.; Wingard, J.R.; Moreb, J.S.: Engraftment syndrome in breast cancer patients after stem cell transplantation is associated with poor long-term survival. *Biol Blood Marrow Transplant.* vol. 7, 2001, pp. 433–8.
141. Bernstein, H.M.; Pollock, B.H.; Calhoun, D.A.; Christensen, R.D.: Administration of recombinant granulocyte colony–stimulating factor to neonates with septicemia: a meta-analysis. *J Pediatrics*, vol. 138, 2001, pp. 917–20.
142. Del Vecchio, A.; Sola, M.C.; Theriaque, D.W.; Hutson, A.D.; Kao, K.J.; Wright, D.; Garcia, M.G.; Pollock, B.H.; Christensen, R. D.: Platelet transfusions in the neonatal intensive care unit: factors predicting which patients will require multiple transfusions. *Transfusion*, vol. 41, 2001 pp. 803–8.
143. Shah, S.J.; Taub, J.W.; Witt, T.L.; Pollock, B.H.; Ding, B.C.; Moore, D.S.; Amylon, M.; Pullen, J.; Ravindranath, Y.; Matherly, L.H.: Relationship of p15 and p16 gene alterations to elevated dihydrofolate reductase in childhood acute lymphoblastic leukaemia. *British J Haematology*, vol. 113, 2001, pp. 746–56.
144. Borst, S.E.; de Hoyos, D.V.; Garzarella, L.; Vincent, K.; Pollock, B.H.; Lowenthal, D.T.; Pollock, M.L.: Effects of resistance training on insulin-like growth factor-I and IGF binding proteins. *Medicine & Science in Sports & Exercise*, vol. 33, 2001, pp. 648–53.
145. Infante, J.R.; Rosenbloom, A.L.; Silverstein, J.H.; Garzarella, L.; Pollock, B.H.: Changes in frequency of limited joint mobility in children with type I diabetes mellitus between 1976–78 and 1998. *J Pediatrics*, vol. 138, 2001, pp. 33–37.
146. Sugrue, M.W.; Williams, K.; Pollock, B.H.; Khan, S.; Peracha, S.; Wingard, J.R.; Moreb, J.S.: Characterization and outcome of “hard to mobilize” lymphoma patients undergoing autologous stem cell transplantation. *Leukemia and Lymphoma*, vol. 39, 2000, pp. 509–19.
147. Pollock, B.H.: Research on the PRO-SELF intervention program. *Seminars in Nursing Oncology*, vol. 16, 2000, pp. 311–314.
148. Mandrell, B.N.; Ruccione, K.; Dodd, M.; Moore, J.; Nelson, A.E.; Pollock, B.; Stewart, J.L.; Stutzer, C.; Westlake, S.K.: Applying the concept of self-care to pediatric oncology patients. *Seminars in Nursing Oncology*, vol. 16, 2000, pp. 315–316.

149. Daniels, J.L.; Olshan, A.F.; Teschke, K.; Hertz–Piciotto, I.; Savitz, D.A.; Blatt, J.; Bondy, M.L.; Neglia, J.P.; Pollock, B.H.; Cohn, S.L.; Look, A.T.; Seeger, R.C.; Castleberry, R.P.: Residential pesticide exposure and neuroblastoma. *Epidemiology*, vol. 12, 2001, pp. 20–7.
150. Yang, Q.; Olshan, A.F.; Bondy, M.L.; Shah, N.R.; Pollock, B.H.; Seeger, R.C.; Look, A.T.; Cohn, S.L.: Parental smoking and alcohol and risk of neuroblastoma. *Cancer Epidemiology Biomarkers & Prevention*, vol. 9, 2000, pp. 967–72.
151. Abshire, T.C.; Pollock, B.H.; Billett, A.L.; Bradley, P.; Buchanan, G.R.: Weekly polyethylene glycol (PEG) conjugated L-asparaginase produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia (ALL): a Pediatric Oncology Group (POG) study. *Blood*, vol. 96, 2000, pp. 1709–15.
152. Pollock, B.H.; DeBaun, M.R.; Camitta, B.; Shuster, J.J.; Ravindranath, Y.; Pullen, D.J.; Land, V.J.; Mahoney, D.H.; Lauer, S.J.; Murphy, S.H.: Ethnic difference in the survival of childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. *J Clin Oncology*, vol. 18, 2000, pp. 813–823.
153. McClain, K.L.; Leach, C.T.; Jenson, H.B.; Joshi, V.V.; Pollock, B.H.; Hutchison, R.E.; Murphy, S.B.: Molecular and virologic characteristics of lymphoid malignancies in children with AIDS. *J Acquired Immune Deficiency Syndrome*, vol. 1, 2000, pp. 152–159.
154. Buchanan, G.R.; Rivera, G.K.; Pollock, B.H.; Boyett, J.M.; Chauvenet, A.R.; Wagner, H.; Maybee, D.A.; Crist, W.M.; Pinkel, D.: Alternating drug pairs with or without periodic reinduction in children with acute lymphoblastic leukemia in second marrow remission: a Pediatric Oncology Group study. *Cancer*, vol. 88, 2000, pp. 1166–1174.
155. Olshan, A.F.; De Roos, A.J.; Teschke, K.; Neglia, J.P.; Stam, D.O.; Pollock, B.H.; Castleberry, R.C.: Neuroblastoma and parental occupation. *Cancer Causes Control*, vol. 10, 1999, pp. 539–549.
156. Pollock, B.H.: Obstacles and opportunities for the use of health-related quality-of-life assessment in pediatric cancer clinical trials. *International J Cancer, Supplement 12*, 1999, pp. 151–153.
157. Ritchey, A.K.; Pollock, B.H.; Lauer, S.L.; Andejeski, Y.; Buchanan, G.R.: Improved survival in children with isolated CNS relapse of acute lymphoblastic leukemia: a Pediatric Oncology Group study. *J Clin Oncology*, vol. 17, 1999, pp. 3745–3752.
158. Olshan, A.F.; Smith, J.; Cook, M.N.; Grufferman, S.; Pollock, B.H.; Stram, D.O.; Seeger, R.C.; Cohn, S.L.; Castleberry, R.C.; Bondy, M.: Hormone and fertility drug use and the risk of neuroblastoma. *Am J Epidemiology*, vol. 150, 1999, pp. 930–938.
159. Ross, J.A.; Swensen, A.R.; Severson, R.K.; Pollock, B.H.; Robison, L.L.; Gurney, J.: Seasonal variations in the diagnosis of childhood cancer in the United States. *British J Cancer*, vol. 81, 1999, pp. 549–553.
160. Severgnini, S.; Lowenthal, D.T.; Millard, W.J.; Simmen, F.A.; Pollock, B.H.; Borst, S.E.: Altered IGF-I and IDGBPs in senescent male and female rats. *Journals of Gerontology Series A: Biological Sciences and Medical Sciences*, vol. 54, 1999, pp. B111–B115.

161. Leach, C.T.; Frantz, C.; Head, D.R.; Gao, S.J.; McClain, K.L.; Cohen, M.; Campbell, A.B.; Pollock, B.H.; Murphy, S.B.; Jenson, H.B.: Human herpesvirus-8 (HHV-8) associated with small non-cleaved cell lymphoma in a child with AIDS. *American J Hematology*, vol. 60, 1999, pp. 215–221.
162. Wafelman, L.S.; Pollock, B.H.; Kreutzeer, J.; Richards, D.S.; Hutchison, A.A.: Nonimmune hydrops fetalis: fetal and neonatal outcome during 1983–1992. *Biology of the Neonate*, vol. 75, 1999, pp. 73–81.
163. James, M.O.; Murali, J.K.M.M.; Cornett, R.; Yan, Z.; Davydova, N.; Henderson, G.N.; Katovich, M.J.; Pollock, B.; Stacpoole, P.W.: Pharmacokinetics and metabolism of [¹⁴C]-dichloroacetate (DCA) in the male Sprague-Dawley rat: identification of glycine conjugates, including hippurate, as urinary metabolites of DCA. *Drug Metabolism Disposition*, vol. 26, 1998, pp. 1134–1143.
164. Rosenbloom, A.L.; Deeb, L.C.; Allen, L.; Pollock, B.H.: Characteristics of pediatric endocrinology practice: a workforce study. *Endocrinologist*, vol. 8, 1998, pp. 2143–218.
165. Silverstein, J.H.; Gordon, G.; Pollock, B.H.; Rosenbloom, A.L.: Long-term glycemic control influences the onset of limited joint mobility in type 1 diabetes. *J Pediatrics*, vol. 132, 1998, pp. 944–947.
166. Kletzel, M.; Abella, E.M.; Sandler, E.S.; Williams, L.L.; Ogden, A.K.; Pollock, B.H.; Wall, D.A.: Thiotepa and cyclophosphamide with stem cell rescue as consolidation therapy for children with high risk neuroblastoma. A phase I/II study of the Pediatric Bone and Marrow Transplant Consortium. *J Ped Hematology/Oncology*, vol. 20, 1998, pp. 49–54
167. Jenson, H.B.; Pollock, B.H.: The role of intravenous immune globulin for prevention and treatment of neonatal sepsis. *Seminars in Perinatology*, vol. 22, 1998, pp. 50–63.
168. Bleyer, W.A.; Tejada, H.; Murphy, S.B.; Robison, L.L.; Ross, J.A.; Pollock, B.H.; Severson, R.K.; Brawley, O.W.; Smith, M.A.; Ungerleider, R.S.: National cancer clinical trials: children have equal access; adolescents do not. *J Adolescent Health*, vol. 21, 1997, pp. 366–373.
169. Friedman, T.; Slayton, W.B.; Allen, L.S.; Pollock, B.H.; Dumont-Driscoll, M.; Mehta, P.; Graham-Pole, J.: Use of alternative therapies for children with cancer. *Pediatrics*, vol. 100, 1997, pp. e1–e6.
170. Jenson, H.B.; Leach, C.T.; McClain, K.L.; Joshi, V.J.; Pollock, B.H.; Parmley, R.T.; Chadwick, E.G.; Murphy, S.M.: Benign and malignant smooth muscle tumors containing Epstein-Barr virus in children with AIDS. *Leukemia and Lymphoma*, vol. 27, 1997, pp. 303–314.
171. Diccianni, M.B.; Batova, A.; Yu, J.; Vu, T.; Pullen, J.; Amylon, M.; Pollock, B.H.; Yu, A.L.: Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions. *Leukemia Research*, vol. 21, 1997, pp. 549–558.
172. Swensen, A.R.; Ross, J.A.; Severson, R.K.; Pollock, B.H.; Robison, L.L.: The age peak in childhood acute lymphoblastic leukemia and the potential relationship with socioeconomic status. *Cancer*, vol. 79, 1997, pp. 2045–2051.
173. Scarpace, P.J.; Matheny, M.; Pollock, B.H.; Tumer, N.: Leptin increases uncoupling protein expression and energy expenditure. *Am J Physiology*, vol. 273, 1997, pp. E226–E230.

174. Bernstein, M.L.; Abshire, T.C.; Pollock, B.H.; Devine, S.; Toledano, S.; Steuber, C.P.; Bowman, W.P.; Buchanan, G.R.: Idarubicin and cytosine arabinoside reinduction therapy for children with multiple recurrent refractory acute lymphoblastic leukemia: A Pediatric Oncology Group study. *J Ped Hematology/Oncology*, vol. 19, 1997, pp. 68–72.
175. Jenson, H.B., Pollock, B.H.: Meta-analyses of the effectiveness of intravenous immune globulin for prevention and treatment of neonatal sepsis, *Pediatrics*, vol. 99, 1997, pp. e2–e12.
176. Bradlyn, A.S.; Ritchey, A.K.; Harris, C.V.; Moore, A.K.; O'Brien, R.T.; Parsons, S.K.; Patterson, K.; Pollock, B.H.: Quality of life research in pediatric oncology: research methods and barriers. *Cancer*, vol. 78, 1996, pp. 1333–1339.
177. Bradlyn, A.S.; Pollock, B.H.: A cooperative group report of quality of life research: lessons learned in the Pediatric Oncology Group. *Monographs J National Cancer Institute*, vol. 20, 1996, pp. 89–90.
178. Bradlyn, A.S.; Pollock, B.H.: Quality-of-life research in the Pediatric Oncology Group: 1991–1995. *Monographs J National Cancer Institute*, vol. 20, 1996, pp. 49–53.
179. Ross, J.A.; Severson, R.K.; Pollock, B.H.; Robison, L.L.: Childhood cancer in the United States: a geographical analysis of cases from the pediatric cooperative clinical trials groups. *Cancer*, vol. 77, 1996, pp. 201–207.
180. Dumont-Driscoll, M.; Barbian, L.; Pollock, B.H.: Pediatric residents' continuity clinics: how are we really doing? *Pediatrics*, vol. 96 (4 Pt 1), 1995, pp. 616–621.
181. McClain, K.L.; Leach, C.T.; Jenson, H.B.; Joshi, V.V.; Pollock, B.H.; Parmley, R.T.; DiCarlo, F.J.; Chadwick, E.G.; Murphy, S.B.: Association of Epstein-Barr virus with leiomyosarcomas of children with AIDS. *New England Journal of Medicine*, vol. 332, 1995, pp. 12–18
182. Sadowitz, P.D.; Dubowy, R.; Souid, A.; Pollock, B.H.; Weinstein, H.; Parmley, R.; Bowman, P.; Land, V.; Vats, T.; Pratt, C.; Buchanan, G.R.: A phase I trial of continuous infusion carboplatin and etoposide in children with refractory acute leukemia. *J Clin Oncology*, vol. 12, 1994, pp. 1969–1973.
183. Carter, E.R.; Stecenko, A.A.; Pollock, B.H.; Jaeger, M.J.: Evaluation of the interrupter technique for the use of assessing airway obstruction in children. *Pediatric Pulmonology*, vol. 17, 1994, pp. 211–217.
184. Pollock, B.H.: Quality assurance for interventions in clinical trials: cooperative group data monitoring, data management and analysis. *Cancer*, vol. 74, 1994, pp. 2647–2652.
185. Rosenbloom, A.L.; Guevara-Aguirre, J.; Rosenfeld, R.G.; Pollock, B.H.: Growth in growth hormone insensitivity. *Trends Endocrinology and Metabolism*, vol. 5, 1994, pp. 296–303.
186. Barrett, A.J., Horowitz, M.M.; Pollock, B.H.; Zhang, M.J.; Bortin, M.M.; Buchanan, G.R.; Camitta, B.M.; Ochs, J.; Graham-Pole, J.; Rowlings, P.A.; Rimm, A.A.; Klein, J.P.; Shuster, J.J.; Sobociniski, K.A.; Gale, R.P.: Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. *New England Journal of Medicine*, vol. 331, 1994, pp. 1253–1258.

187. Golergant, D.; Dumont-Driscoll, M.; Pollock, B.H.; Eitzman, D.; Neiberger, R.E.: Oral rehydration therapy: North Florida physician's attitudes. *J Florida Medical Association*, vol. 81, 1994, pp. 539–542.
188. Lauer, S.J.; Ochs, J.; Pollock, B.H.; Buchanan, G.R.: Recombinant alpha-2b interferon treatment for childhood T-lymphoblastic disease in relapse: a Pediatric Oncology Group phase II study. *Cancer*, vol. 74, 1994, pp. 197–202.
189. Katz, J.A.; Pollock, B.H.; Jacaruso, J.; Morad, A.: Final attained height in patients successfully treated for childhood acute lymphoblastic leukemia. *J Pediatrics*, vol. 123, 1993, pp. 546–552.
190. Roush, S.W.; Krischer, J.P.; Cox, M.W.; Pollock, B.H.: Socioeconomic and demographic factors that predict where children receive cancer care in Florida. *J Clin Epidemiology*, vol. 46, 1993, pp. 535–544.
191. Ross, J.A.; Severson, R.K.; Robison, L.L.; Pollock, B.H.; Neglia, J.P.; Woods, W.G.; Hammond, G.D.: Pediatric cancer in the United States: a collaborative intergroup study with the Children's Cancer Study Group and the Pediatric Oncology Group. *Cancer*, vol. 71 (10 Supplement), 1993, pp. 3415–3421.
192. Krischer, J.P.; Roush, S.W.; Cox, M.W.; Pollock, B.H.: Using a population-based registry to identify patterns of care in childhood cancer in Florida. *Cancer*, vol. 71 (10 Supplement), 1993, pp. 3331–3336.
193. Lang, F.P.; Pollock, B.H.; Riley, W.J.; Maclaren, N.K.; Barrett, D.J.: The temporal association between gamma delta T cells and the natural history of insulin-dependent diabetes. *J Autoimmunity*, vol. 1, 1993, pp. 107–119.
194. Vietti, J.; Shuster, J.; Amylon, M.; Berard, C.; Borowitz, M.; Bowman, P.; Brecher, M.; Castleberry, R.; Frankel, L.; Falletta, J.; Goorin, A.; Hayes, A.; Hvizdala, E.; Krischer, J.; Land, V.; Link, M.; McWilliams, N.; Murphy, S.; Pick, T.; Pollock, B.; Pullen, J.; Ravindranath, Y.; Smith, E.I.; Steuber, C.P.; Sullivan, M.; van Eys, J.; Wharam, M.; Crist, W.: Progress against childhood cancer: The Pediatric Oncology Group experience. *Pediatrics*, vol. 89, 1992, pp. 597–600.
195. Roush, S.W.; Krischer, J.P.; Pollock, N.C.; Cox, M.W.; Pollock, B.H.; Bayer, J.: the incidence of pediatric cancer in Florida, 1981–1986. *Cancer*, vol. 69, 1992, pp. 2212–2219.
196. Lang, F.P.; Schatz, D.A.; Pollock, B.H.; Riley, W.J.; Maclaren, N.K.; Dumont-Driscoll, M.; Barrett, D.J.: Increased T lymphocytes bearing the gamma-delta T cell receptor in subjects at high risk for insulin dependent diabetes. *J Autoimmunity*, vol. 4, 1991, pp. 925–933.
197. Pollock, B.H.; Krischer, J.P.; Vietti, T.J.: The interval between symptom onset and diagnosis of pediatric solid tumors. *J Pediatrics*, vol. 119, 1991, pp. 725–732.
198. Buchanan, G.R.; Boyett, J.M.; Pollock, B.H.; Smith, S.D.; Yanofsky, R.; Kim, T.; Wharam, M.; Crist, W.; Vietti, T.J.; Rivera, G.; Johnson, W.: Improved treatment results in boys with isolated overt testicular relapse during or shortly following initial therapy of acute lymphoblastic leukemia: A Pediatric Oncology Group study. *Cancer*, vol. 68, 1991, pp. 48–55.

199. Ochs, J.; Brecher, M.; Mahoney, D.; Vega, R.; Pollock, B.; Buchanan, G.; Whitehead, M.; Ravindranath, Y.; Freeman, A.: Recombinant interferon alpha given before and in combination with standard chemotherapy in children with acute lymphoblastic leukemia in first marrow relapse: A pediatric Oncology Group pilot study. *J Clin Oncology*, vol. 9, 1991, pp. 777–782.
200. Ochs, J.; Rivera, G.; Pollock, B.; Buchanan, G.; Crist, W.; Freeman, A.: Teniposide (VM-26) and continuous infusion cytosine arabinoside for initial induction failure in childhood acute lymphoblastic leukemia. A Pediatric Oncology Group Pilot Study. *Cancer*, vol. 66, 1990, pp. 1671–1677.
201. Pollock, B.H.; Diamond, G.A.: Accuracy of heuristic and algorithmic interpretations of cardiac stress tests in comparison to expert clinicians. *Am J Noninvasive Cardiology*, vol. 2, 1988, pp. 339–346.
202. Bobbio, M.; Pollock, B.H., Cohen, I.; Diamond, G.A.: Comparative accuracy of clinical tests for diagnosis and prognosis of coronary artery disease. *Am J Cardiology*, vol. 62, 1988, pp. 896–900.
203. Diamond, G.A.; Pollock G.H.; Work, J.W.: Clinician decisions and computers. *J Am College of Cardiology*, vol. 9, 1987, pp. 1385–1396.
204. Ladenheim, M.L.; Kotler, T.S.; Pollock, B.H.; Berman, D.S.; diamond, G.A.: Incremental prognostic power of the clinical history, exercise electrocardiography and myocardial perfusion scintigraphy in suspected coronary artery disease. *Am J Cardiology*, vol. 59, 1987, pp. 270–277.
205. Pollock, B.H.; Diamond, G.A.: Heuristic and algorithmic interpretation of cardiac stress tests. *Proceedings of the American Association of Medical Systems and Informatics*, vol. 5, 1986, pp. 204–208.
206. Ladenheim, M.L.; Pollock, B.H.; Rozanski, A.; Berman, D.S.; Staniloff, H.M.; Forrester, J.S.; Diamond, G.A.: Extent and severity of myocardial hypoperfusion as predictors of prognosis in patients with suspected coronary artery disease. *J American College of Cardiology*, vol. 7, 1986, pp. 464–471.
207. Diamond, G.A.; Rozanski, A.; Forrester, J.S.; Morris, D.; Pollock, B.H.; Staniloff, H.M.; Berman, D.S.; Swan, H.J.C.: A model for assessing the sensitivity and specificity of test subject to selection bias: application to exercise radionuclide ventriculography for diagnosis of coronary artery disease. *J Chronic Diseases*, vol. 39, 1986, pp. 349–355.
208. Pollock, B.H.; Diamond, G.A.: CADENZA: Computer-aided diagnosis. *Medical Electronics*, vol. 16, 1985, pp. 95–101.
209. Rozanski, A., Diamond, G.A.; Jones, R.; Forrester, J.S.; Berman, D.; Morris, D.; Pollock, B.H.; Freeman, M.; Swan, H.J.C.: A Format for integrating the interpretation of exercise ejection fraction and wall motion and its application in identifying equivocal responses. *J American College of Cardiology*, vol. 5, 1985, pp. 238–248.
210. Staniloff, H.M.; Diamond, G.A.; Pollock, B.H.: Probabilistic diagnosis and prognosis of coronary artery disease. *J Cardiac Rehabilitation*, vol. 4, 1984, pp. 518–529.
211. Pollock, B.H.; Staniloff, H.M.; Diamond, G.A.: Computer-assisted interpretation of multiple tests. *Cardiovascular Reviews and Reports*, vol. 4, 1983, pp. 367–375.

212. Diamond, G.A.; Staniloff, H.M.; Forrester, J.S.; Pollock, B.H.; Swan, H.J.C.: Computer-assisted diagnosis in the noninvasive evaluation of patients with suspected coronary artery disease. *J Am College of Cardiology*, vol. 1, 1983, pp. 444–455.

Non-Refereed Publications

1. Kean, M.A.; Abernethy, A.P.; Clark, A.M.; Dalton, W.S.; Pollock, B.H.; Shulman, L.N.; Murphy, S.B.: Achieving Data Liquidity in the Cancer Community: Proposal for a Coalition of All Stakeholders. National Academy of Sciences, 2012.
2. Pollock, B.H.: Ph.D. Dissertation: *Prognostic Testing in Coronary Artery Disease*. University Microfilms Service Dissertation Information Service, Ann Arbor MI, 1988.

3. Abstracts:

1. Inkelas, M.; Mittman, B.; Handley, M.; Bender, M.; Pollock, B.; Nguyen, O.; Aarons, G.; Cousineau, M.; Sak, R.: Identifying educational needs of researchers and health system and health agency leaders in the science of implementation and improvement: Report from California CTSAs. *Journal of Clinical and Translational Science*, vol. 4(S1), pp. 134-134. doi:10.1017/cts.2020.397, 2020.
2. Winestone, L.; McPheeters, J.; Puccetti, D.; Wilkes, J.J.; Muffly, L.; Kahn, J.; Henk, H.J.; Ginsberg, J.; Keegan, T.; Pollock, B.H.; Alvarez, E.M.: Delays in diagnosis in young patients with leukemia and lymphoma. *J Clinical Oncology*. 2019, vol. 37, p. e18138-e18138. 10.1200/JCO.2019.37.15_suppl.e18138.
3. Flores, Y.N.; Sanchez, G.J.; ten Hoeve, J.; Amoon, A.T.; Graeber, T.; Glenn, B.A.; May, F.P.; Durazo, F.; Zhang, Z-F.; Salmerón, J.; Pollock, B.H.; Bastani, R.: Metabolic dysregulation and risk of non-alcoholic fatty liver disease in Mexican adults. *AACR Annual Meeting Proceedings* (in press).
4. Livingston, J.; Mette, L.; Thomas, M.H.; Aguilar, C.; Pollock, B.; Tysinger, J.; Tomlinson, G.: GRACIAS Texas: Cancer genetics education in South Texas using the ACGME core competencies as a framework for training primary care providers and physicians-in-training. Poster presentation at the International Cancer Education Conference, Cleveland, OH., September 2017.
5. Pollock, B.H.; Elmore, S.E.; Romoser, A.; Tang, L.; Kang, M.; Xue, K.; Rodriguez, M.; Jaime, N.; Hayes, H.; A Hansen, A.; Guerra, F.; Wang, J-S; Phillips, T.D.: Reduction of aflatoxin bioavailability with ACCS₁₀₀ in an exposed South Texas population, *Annals Epidemiology*, 2015, 25:704.
6. Mazumdar, M.; Messinger, S.; Finkelstein, D.; Goldberg, J.; Lindsell, C.; Morton, S.; Pollock, B.; Rahbar, M.; Welty, L.; Parker, R.: Evaluating scientists collaborating in team-based research: a proposed framework. *Translational Science* 2015. Washington DC. April 18, 2015.
7. Freyer, D.R.; Chen, L.; Pollock, B.H.; Knight, K.; Bliss, B.; Ramdas, J.; VanSoelen, M.; VanHoff, D.; Wiernikowski, J.; Rassekh, S.R.; Sung, L.; Neuwelt, E.A.: The Effects of Sodium Thiosulfate (STS) on Cisplatin-induced Hearing Loss: A Report from the Children’s Oncology Group. *Journal Clinical Oncology* 32, 2014, suppl; Abstr 10017.

8. Bansal, H.; Chen, T.; Lai, Z.; Parsons, D.W.; Trevino, L.; Lopez-Terrada, D.; Finegold, M.; Rakheja, D.; Comerford, S.; Hammer, R.; Pollock, B.H.; Hung, J.Y.; Bansal, S.; Chen, Y.; Tomlinson, G.E.: Silencing of nuclear factor (erythroid-derived 2)-like 2 (NFE2L2) impairs growth and proliferation of hepatoblastoma cells; San Diego, CA. Nov. 2013, American Association for Cancer Research Special Conference “Pediatric Cancer at the Crossroads.”
9. Sukeshi, R. Patel; Ketchum, N.; Pollock, B.H.; Sarantopoulos, J.; Weitman, S.; Mahalingam, D.: Beyond VEGF inhibition: Comparative efficacy analysis of novel VEGF and non-VEGF therapeutic agents in phase I trials for patients with metastatic colorectal cancer (mCRC). *Journal Clinical Oncology* 31, 2013, suppl; Abstr 3541.
10. Al-Rajabi, R.M.; Ketchum, N.; Dierschke, N.D.; Lu, T.W.; Pollock, B.H.; Mahalingam, D.: Comparative efficacy and safety analysis of sorafenib in patients with advanced hepatocellular cancer (HCC) with varying liver dysfunction: A south Texas institutional analysis. *Journal Clinical Oncology* 31, 2013, suppl; Abstr e15171.
11. Weitman, S.D.; Ramirez, A.G.; Chalela, P.; Munoz, E.; Pollock, B.H.: Overcoming the barriers to early-phase clinical trials (EPCT): Increasing EPCT minority accrual. *Journal Clinical Oncology* 30, 2012, suppl; Abstr e16566.
12. Infante, T.D.; Arévalo-Flechas, L.C.; Ford, L.A.; Partida, N.S. Ketchum, N.; Pollock, B.H.; Infante, A.J.: Realizing enhanced student inter-professional education through clinical teamwork (RESPECT). 7th Annual Innovations in Health Science Education Conference Proceedings, 2012.
13. Tomlinson, G.E.; Torres, I.; Thomas, M.; Aguilar, C.; Pollock, B.H.; Tysinger, J.W.: GRACIAS Texas!—Genetic Risk assessment for Cancer in All South Texas: Implementing Professional Education Genetic Services in an Underserved Area Oct. 2012, Cancer Prevention Research Institute of Texas Annual Meeting, Austin, Texas.
14. Pollock, B.H.; Sullivan, D.C.: Databases for clinical translational research: repurposing and designing for unanticipated needs. *Clinical Translational Science*, vol. 4, April 2011, p. 96.
15. Frei, C.R.; Parchman, M.L.; Forcade, N.A.; Du, L.C.; Nyren, N.R.; Treviño, L.; Peña, J.; Mann, M.; Muñoz, A.; Treviño, S.; Mortensen, E.; Wickes, B.; Pollock, B.H.; Jorgensen, J.H.: Incidence, severity, and treatment of community-acquired MRSA (CA-MRSA) skin and soft tissue infections (SSTI) in 12 medical clinical in Texas. *Clinical Translational Science*, vol. 4, April 2011, p. 100.
16. Pollock, B.; Sparks, C.: Geographic incidence patterns of primary liver cancer in Bexar County, Texas. abstr. 140, 2010 Innovations in Cancer Prevention and Research Abstract Presentation, Cancer Prevention & Research Institute of Texas, Austin, TX.
17. Tomlinson, G.; Lopez-Terrada, D.; Finegold, M.; Parsons, D.; Chintagumpala, S.; Comerford, S.; Hammer, R.; Rakheja, D; Pollock, B.; Chen, Y.: Genetics and biology of liver tumorigenesis in children: a multi-investigator research collaboration. abstr. 26, 2010 Innovations in Cancer Prevention and Research Abstract Presentation, Cancer Prevention & Research Institute of Texas, Austin, TX.
18. Beuten, J.; Piwkham, D.; Gelfond, J.A.L.; Collier III, A.; Pakakasama, S.; Pollock, B.H., Tomlinson, G.E.: Association analysis of candidate genes in childhood acute lymphoblastic leukemia Washington, DC, 60th Annual American Society of Human Genetics Meeting, Nov. 2010.

19. Beuten, J.; Piwkham, D.; Gelfond, J.; Collier, III, A.; Pakakasama, S.; Pollock, B.; Tomlinson, G.: Association analysis of candidate genes in non-Hispanic and Hispanic children with acute lymphoblastic leukemia. Abstr. 5. 2010 Innovations in Cancer Prevention and Research Abstract Presentation, Cancer Prevention & Research Institute of Texas, Austin, TX.
20. Harris, M.; Rosende, C.A.; Pollock, B.H.; Ballentine, C.S.: Incidence of Follow-up Examinations Within a Remote Diabetic Screening Program, E-Abstract #2506, Invest Ophthalmol Vis Sci, vol. 50, pp. 2506-2506, 2009.
21. Pandya, D. M.; Peterson, L.; Pollock, B.H.; Karnad, A.: Breast cancer survivorship (CS): A comparison of perceptions in the acute and extended survival phases. Journal Clinical Oncology Programs/Proceedings of the American Society of Clinical Oncology, vol. 26, May 20, 2008, suppl; abstr 20599.
22. Grabinski, J. L. ; Chisholm, G.; Smith, L. S.; Drengler, R. L.; Kalter, S.; Rodriguez, G.; Garner, A.; Cooper, J.; Pollock, B.; Kuhn, J.: ER alpha genotypes and breast cancer recurrence. Journal Clinical Oncology. Programs/Proceedings of the American Society of Clinical Oncology, vol. 26, May 20 2008, abstr 501.
23. Kato, P.M.; Pollock, B.H.; Dahl, G.V.; Baggott, C.R.; Beale, I.L.; Marín-Bowling, V.M.; Cole, S.W.: The effect of a video game on self-care and quality of life among adolescents and young adults with cancer: a randomized controlled trial, Teen Cancer Trust, March 31, 2006, London, England.
24. Kato, P.M.; Cole, S.W.; Marín-Bowling, V.M.; Dahl, G.V; Pollock, B.H.: Controlled trial of a video game to improve health-related outcomes among adolescents and young adults with cancer. Society for Behavioral Medicine, March 23, 2006, San Francisco, CA.
25. Grabinski, J. L.; Smith, L. S.; Chisholm, G.; Drengler, R. L.; Rodriguez, G.; Lang, A.S.; Kalter, S.; Garner, A.M.; Fichtel, L.M.; Pollock, B.H.; Kuhn, J.G.: Relationship between CYP2D6 and estrogen receptor alpha polymorphisms on tamoxifen metabolism in adjuvant breast cancer treatment. Journal Clinical Oncology. Programs/Proceedings of the American Society of Clinical Oncology, vol. 24(No. 18S suppl), June 20 2006, p. 505.
26. Learn, P.A.; Yeh, I.; McNutt, M.; Chisholm, G. B.; Pollock, B. H.; Rousseau, D. L.; Sharkey, F. E.; Cruz, A. B.; Kahlenberg, M. S.: HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in operable breast cancer. Journal Clinical Oncology. Programs/Proceedings of the American Society of Clinical Oncology, vol. 23 (No. 16S suppl), June 1 2005, abstr. 9569.
27. Yeh, I.-T.; Sharkey, F.E.; Kahlenberg, M.S.; Pollock, B.H.; Frome, A.I.; McNutt, M.K.; Miller, A.R.; Cruz, A.B.: Effect of neoadjuvant chemotherapy on breast cancer IHC prognostic markers. 2005 United States and Canadian Academy of Pathology Annual Meeting.
28. Sun, L.; Bandyopadhyay, A.M.; Wang, L.; Agyin, J.K.; Mundy, G.R.; Pollock, B.H.: Blockade of Transforming Growth Factor-beta (TGFβ) signaling inhibits breast cancer metastasis to bone in an experimental animal model of bone metastasis, (Keystone Symposium—roles of TGF-β in Disease Pathogenesis: Novel Therapeutic Strategies, Keystone, CO, Mar. 2005.

29. Zafar, H.; Pollock, B.; Yeh, I.-T.; Knight, W.: Her-2/Neu over expression in patients with breast cancer and early central nervous system (CNS) relapse. *Journal Clinical Oncology*, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition), vol. 22 (No 14S), July 15 2004 Supplement), abst. 707.
30. Kahlenberg, M. S.; Stefanidis, D.; Miranda, J.; Wong, A.; Thomas, C.; Rousseau, D.; Pollock, B.: Colorectal cancer in Hispanics: A population at risk for earlier onset, advanced disease and decreased survival, 2004, ASCO Gastrointestinal Cancers Symposium, abst. 276.
31. Dicciani, M.B.; Shue, E.H.; Pollock, B.H.; Yu, A.L.: Expression of Hox11 but Not Hox11L2 Is Associated with Relapsed T-Cell Acute Lymphoblastic Leukemia. *Blood*, vol. 102, 2003, p. 22a.
32. Grufferman, S.; Pollock, B.H.; Brecher, M.K.; Taylor, J.A.; Schwartz, C.L.; Ambinder, R.F.: A protective effect of breast-feeding on risk of Hodgkin's disease in children. The Children's Oncology Group. Proceedings of the Fifth International Symposium on Hodgkin's Lymphoma, 2001.
33. Grufferman, S.; Gilchrist, G.S.; Pollock, B.H.; Taylor, G.M.; Schwartz, C.L.; Ambinder, R.F.: Socioeconomic status, the Epstein-Barr virus and risk of Hodgkin's disease in children. The Children's Oncology Group. Proceedings of the Fifth International Symposium on Hodgkin's Lymphoma, 2001.
34. Garcia, M.G.; Pollock, B.H.; Garzarella, L.; Christensen, R.D.: Effect of recombinant erythropoietin, administered to very low birth-weight infants, on erythrocyte transfusions during the first three weeks of life: a meta-analysis. *Pediatric Research*, vol. 49, 2001, p. 321A.
35. Bernstein, H.M.; Pollock, B.H.; Calhoun, D.A.; Christensen, R.D.: Administration of recombinant granulocyte colony-stimulating factor (rG-CSF) to neonates with sepsis: a meta-analysis. *Pediatric Research*, vol. 49, 2001, p. 227A.
36. De Ross, A.J.; Olshan, A.F.; Teschke, K.; Poole, C.; Pollock, B.H.; Bondy, M.L.: Parental occupational exposures to chemicals and the incidence of neuroblastoma in offspring. *American Journal of Epidemiology*, vol. 151, 2000, p. S47.
37. Minn, Y.A.; Pollock, B.H.; Garzarella, L.; Dahl, G.V., Kun, L.E.; Ducore, J.M.; Shibata, A.; Kepner, J.; Fisher, P.G.: Surveillance neuroimaging to detect relapse in childhood brain tumors: a Pediatric Oncology Group study. *Programs/Proceedings of the American Society of Clinical Oncology*, vol. 19, March 2000, p. 582a.
38. Mehta, P.S.; Pollock, B.; Wingard, J.R.; Nugent, M.; Horowitz, M.; Confer, D. Gender access to stem cell transplantation (SCT). *Blood*, vol. 94 (10 supplement), 1999, p. 187a.
39. Ross, J.A.; Swensen, A.R.; Severson, R.K.; Pollock, B.H.; Robison, L.L.: Seasonal trends in the diagnosis of childhood cancer. *American Journal of Epidemiology*, vol. 147, 1998, p. S43.
40. del Rosario, M.L.U.; NeJame, C.F.; Allen, L.S.; Scotti, D.B.; Medei, M.E.; Boyette, R.L.; Enting, W.L., Lottenberg, R.; Kao, K.J.; Pollock, B.H.; Wingard, J.R.: Incidence of bleeding and platelet utilization following hemopoietic stem cell transplantation (HSCT). *Blood*, vol. 92 (10 supplement), 1998, p. 321b.

41. del Rosario, M.L.U.; NeJame, C.F.; Rodrigue, J.R.; Allen, L.S.; Pollock, B.H.; Lottenberg, R.; Kao, K.J., Wingard, J.R. Short-term changes in health-related quality of life (QOL) following hemopoietic stem cell transplantation (HSCT). *Blood*, vol. 92 (10 supplement), 1998, p. 456a.
42. Shah, S.J.; Taub, J.W.; Radewan, T.L.; Fu, W.; Moore, D.; Pollock, B.H.; Zhang, L.; Amylon, M.; Behm, F.G.; Pullen, J.; Ravindranath, Y.; Matherly, L.H.: Relationship of p15 and p16 gene deletions to elevated dihydrofolate reductase (DHFR) in childhood acute lymphoblastic leukemia (ALL). *Blood*, vol. 92 (10 supplement), 1998, p. 220a.
43. Pollock, B.H.; DeBaun, M.R.; Camitta, B.; Shuster, J.J. Pullen, D.J.; Murphy, S.B.: Ethnic differences in the survival of childhood B-precursor acute lymphoblastic leukemia. *American Journal of Epidemiology*, vol. 147, 1998, p. S46.
44. Daniels, J.D.; Olshan, A.F.; Teschke, K.; Bondy, M.; Shah, N.; Castleberry, R.P.; Pollock, B.H.: Parental residential pesticide exposure and the risk of neuroblastoma. *American Journal of Epidemiology*, vol. 147, 1998, p. S44.
45. Homans, A.; Kurtzberg, J.; Pollock, B.; DeOliveira, D.; Billett, A.: Comparison of polyethylene glycol conjugated (PEG) L-Asparaginase (ASP) with native E. coli ASP for induction therapy of relapsed childhood acute lymphoblastic leukemia (ALL): a Pediatric Oncology Group study. *Programs/Proceedings of the American Society of Clinical Oncology*, vol. 17, March 1998, p. 221a.
46. Leach, C.T.; Frantz, C.; McClain, K.L.; Cohen, M.; Campbell, A.B.; Pollock, B.H.; Murphy, S.B.; Jenson, H.B.: Human herpesvirus-8 associated with small non-cleaved cell lymphoma in a child with acquired immunodeficiency syndrome. *Second International Conference on Human Herpes Viruses 6, 7 and 8*. Pisa, Italy, May 8, 1997.
47. Billett, A.L.; Pollock, B.H.; Abshire, T.C., Buchanan, G.R.: Outcome of children with B-lineage acute lymphoblastic leukemia (ALL) in first bone marrow relapse. *Blood*, vol. 90 (10 supplement), 1997, p. 332a.
48. Farah, R.A.; Billett, A.L.; Pollock, B.H.; Buchanan, G.R.; Schneider, N.R.: Significance of cytogenetic findings in childhood acute lymphoblastic leukemia (ALL) at first relapse: A pediatric oncology group (POG) study. *Blood*, vol. 90 (10 supplement); 1997, p. 185a.
49. Pollock, B.H.; Jenson, H.B.; McClain, K.L.; Leach, C.T.; Joshi, V.V.; Murphy, S.B.: Risk factors for HIV-related malignancies in children, *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology*, vol. 14, 1997, p. A17.
50. Pollock, B.H.; Jenson, H.B.; McClain, K.L.; Leach, C.T.; Joshi, V.V.; Murphy, S.B.: Risk factors for pediatric HIV-related malignancies, *American Journal of Epidemiology*, vol. 145, 1997, p. S6.
51. Diccianni, M.B.; Batova, A.; Vu, T.; Pollock, B.; Yu, A.L.: Clinical significance of p16 gene deletions in T-cell acute lymphoblastic leukemia.. *Proceedings of the American Association for Cancer Research*, vol. 37, March 1996, p. 590.
52. Abshire, T.; Pollock, B.; Billett, A.; Bradley, P.; Buchanan, G.: Weekly polyethylene glycol conjugated (PEG) L-asparaginase (ASP) produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia (rALL): A Pediatric Oncology Group Study 9310. *Programs/Proceedings of the American Society of Clinical Oncology*, vol. 14, March 1995, p. 344.

53. Bernstein, M.; Abshire, T.; Devine, S.; Pollock, B.H.; Buchanan, G.R.: Idarubicin (IDA) and cytarabine (ARA-C) (IA) induction followed by ifosfamide (IFOS) and etoposide (VP) (IE) alternating with IA continuation therapy in refractory or multiply relapsed childhood acute lymphoblastic leukemia (ALL): A Pediatric Oncology Group (POG) study. *Programs/Proceedings of the Journal of the American Society for Pediatric Hematology/Oncology*, vol. 13, 1994, p 317.
54. McClain, K.L.; Leach, C.T.; Jenson, H.B.; Joshi, V.V.; Pollock, B.H.; Parmley, R.T.; DiCarlo, F.J.; Chadwick, E.G.; Murphy, S.B.: Epstein-Barr virus is associated with leiomyomas and leiomyosarcomas of children with AIDS. The 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, FL, October 4-7, 1994.
55. Barrett, A.J.; Pollock, B.; Horowitz, M.M.; Zhang, M.J.; Gale, R.P.: Chemotherapy versus bone marrow transplant with acute lymphoblastic leukemia in second remission. *Blood*, vol. 82, 1993, p. 194a.
56. Ritchey, A.K.; Pollock, B.H.; Lauer, S.; Homans, A., Newman, E.; Andejaski, Y.: Delayed craniospinal irradiation (CS RT) with intensified chemotherapy for isolated meningeal relapse of childhood acute lymphoblastic leukemia (ALL). *Blood*, vol. 82, 1993, p. 195a.
57. Maybee, D.; Dubowy, R.; Pollock, B.; Lucas, M.; Weinstein, H.: Inadequacy of standard toxicity criteria in evaluating complications of high-dose α -interferon (α IFN) in children with Ph⁺ chronic myelogenous leukemia (CML). *Programs/Proceedings of the Journal of the American Society for Pediatric Hematology/Oncology*, vol. 2, 1993, p 46.
58. Golergant, D.; Dumont-Driscoll, M.; Eitzman, D.; Pollock, B.H.; Neiberger, R.: Oral rehydration therapy in North Central Florida. *Clinical Research*, vol. 41 (4), 1993, p. 727A.
59. Kurtzberg, J.; Asselin, B.; Pollock, B.; Bernstein, M.; Buchanan, G.: PEG-L-asparaginase vs. native *E. Coli* asparaginase for reinduction of relapsed acute lymphoblastic leukemia (ALL): POG #8866 phase II trial. *Program/Proceedings of the American Society of Clinical Oncology*, vol. 12, March 1993, No. 1079, p. 325.
60. Katz, J.A.; Pollock, B.H.: Final adult height in long-term survivors of childhood acute lymphoblastic leukemia (ALL) treated with or without cranial irradiation (CI): a Pediatric Oncology Group (POG) study. *Program/Proceedings of the American Society of Clinical Oncology*, vol. 11, March 1992, No. 941, p. 283.
61. Ross, J.A.; Severson, R.K.; Robison, L.L.; Pollock, B.H.; Neglia, J.P.; Hammond, G.D.: Distribution of pediatric cancer in the United States: a geographical analysis of patients seen at cooperative group institutions. *Program/Proceedings of the American Society of Clinical Oncology*, vol. 10, 1991, No. 399.
62. Ferguson, J.G.; Pollock, B.H.; Work, J.W.; Diamond, G.A.: Mixmastering: multiveritable analysis of a multivariable model. *Clinical Research*, vol. 36, 1988, p. 335.
63. Ferguson, J.G.; Pollock, B.H.; Work, J.W.; Diamond, G.A.: How reliable are clinical prediction models? *Circulation*, vol. 76 (4) Supplement II, p. 253, 1987.
64. Pollock, B.H.; Ferguson, J.G.; Diamond, G.A.: How important is the raw data? *Clinical Research*, vol. 35, 1987, p. 314.
65. Pollock, B.H.; Ferguson, J.G.; Diamond, G.A.: Do clinical prediction rules really mean what they say? *Clinical Research*, vol. 35, 1987, p. 358.

66. Ferguson, J.G.; Pollock, B.H.; Work, J.W.; Diamond, G.A.: Is bigger really better? *Clinical Research*, vol. 35, 1987, p. 344.
67. Ferguson, J.G.; Pollock, B.H.; Work, J.W.; Diamond, G.A.: How precise are estimates of precision? *Clinical Research*, vol. 35, 1987, p. 344.
68. Ferguson, J.G.; Pollock, B.H.; Work, J.W.; Diamond, G.A.: How does sample size affect the reproducibility of a clinical prediction rule? *Clinical Research*, vol. 35, 1987, p. 344.
69. Ferguson, J.G.; Pollock, B.H.; Work, J.W.; Diamond, G.A.: How does loss to follow-up affect the reproducibility of a clinical prediction rule? *Clinical Research*, vol. 35, 1987, p. 344.
70. Pollock, B.H.; Ladenheim, M.L.; Diamond, G.A.: Validation of an expert computer system for interpretation of cardiac stress tests. *Circulation*, vol. 74, 1986, p. II-500.
71. Pollock, B.H.; Bobbio, M.; Kotler, T.S.; Work, J.W.; Berman, D.S.; Diamond, G.A.: Is diagnosis more accurate than prognosis? *Circulation*, vol. 74, 1986, p. II-222.
72. Kotler, T.S.; Work, J.W.; Berman, D.S.; Pollock, B.H.; Diamond, G.A.: Is the prognostic value of exercise radionuclide angiography dependent on its diagnostic value? *Journal of Nuclear Medicine*, vol. 27, 1986, p. 926.
73. Pollock, B.H.; Diamond, G.A.: Accuracy of a heuristic computer program for the diagnosis of coronary artery disease. *Clinical Research*, vol. 34, 1986, p. 380.
74. Bobbio, M.; Keyes, C.; Rozanski, A.; Pollock, B.H.; Diamond, G.A.: Can physicians identify equivocal responses? *Clinical Research*, vol. 34, 1986, p. 359.
75. Bobbio, M.; Rozanski, A.; Pollock, B.H.; Diamond, G.A.: Why do physicians estimate probabilities erroneously? *Clinical Research*, vol. 34, 1986, p. 359.
76. Work, J.W.; Pollock, B.H.; Kotler, T.S.; Berman, D.S.; Diamond, G.A.: Does diagnostic uncertainty influence referral for testing? *Clinical Research*, vol. 34, 1986, p. 387.
77. Pollock, B.H.; Bobbio, M.; Kotler, T.S.; Work, J.W.; Berman, D.S.; Diamond, G.A.: How difficult is it to predict the future? *Clinical Research*, vol. 34, 1986, p. 336.
78. Kotler, T.S.; Pollock, B.H.; Work, J.W.; Diamond, G.A.: Prognostic stratification by thallium scintigraphy: who needs it? *Journal of the American College of Cardiology*, vol. 7, 1986, p. 232.
79. Ladenheim, M.L.; Pollock, B.H.; Rozanski, A.; Berman, D.S.; Staniloff, H.S.; Forrester, J.S.; Diamond, G.A.: Extent and severity of myocardial hypoperfusion as independent indices of prognosis. *Circulation*, vol. 72, 1985, p. III-137.
80. Ladenheim, M.L.; Pollock, B.H.; Diamond, G.A.: Prognostic accuracy depends on both the patient and the test. *Circulation*, vol. 72, 1985, p. III-465.
81. Staniloff, H.M.; Berman, D.S.; Forrester, J.S.; Diamond, G.A.; Maddahi, J.; Rozanski, A.; Pollock, B.H.; Swan, H.J.C.: Equivocal stress thallium scintigrams do not have an equivocal prognosis. *Circulation*, vol. 72, 1985, p. III.
82. Rozanski, A.; Diamond, G.A.; Jones, R.H.; Forrester, J.S.; Berman, D.S.; Morris, D.; Pollock, B.H.; Freeman, M.; Swan, H.J.C.: Detecting equivocal test responses. *Circulation* vol. 70, 1984, p. II-286.
83. Staniloff, H.S.; Forrester, J.S.; Diamond, G.A.; Pollock, B.H.; Swan, H.J.C.: The "CABG" patch: classification of coronary artery bypass surgical crossovers in medical studies. *Clinical Research*, vol. 32, 1984, p. 228.

84. Staniloff, H.M.; Diamond, G.A.; Forrester, J.S.; Pollock, B.H.; Berman, D.S.; Swan, H.J.C.: The powerful predictor pitfall in prognostication. *Circulation* vol. 68, 1983, p. III-136.
85. Staniloff, H.M.; Diamond, G.A.; Forrester, J.S.; Pollock, B.H.; Berman, D.S.; Swan, H.J.C.: Superiority of multivariate vs univariate analysis in predicting cardiac events after myocardial infarction. *Journal of the American College of Cardiology*, vol. 1, 1983, p. 655.
86. Rozanski, A.; Diamond, G.; Berman, D.; Morris, D.; Pollock, B.; Swan, H.J.C.: Can probability analysis predict the ejection fraction response to exercise? *Clinical Research*, vol. 31, 1983, p. 17A.
87. Staniloff, H.M.; Diamond, G.A.; Forrester, J.S.; Pollock, B.H.; Berman, D.S.; Swan, H.J.C.: The incremental informational boondoggle: when a test result seems powerful but isn't. *Circulation*, vol. 66, 1982, p. 184.
88. Pollock, B.H.; Diamond, G.A.; Staniloff, H.M.; Forrester, J.S.: Accurate computer assessment of clinical coronary artery disease. *Medical Decision Making*, vol. 2, 1982, p. 365.

4. Other:

“The Future of Public Health in Texas 2005,” Task Force on the Future of Public Health in Texas, University of Texas System, 2005.

Potter, L. B., Sparks, C., & Pollock, B. (2016, September 22). Recent Trends and Characteristics Associated with Influenza Vaccination Disparities among Texas Children. Open Science Framework. Retrieved from osf.io/preprints/socarxiv/8mnwv

5. Papers Submitted:

1. Phillips, C.A.; Barakat, L.P.; Pollock, B.H.; Bailey, L.C.; Beidas, R.S.: Implementation science in pediatric oncology: a narrative review and future directions.
2. Abdelhadi, O.A.; Pollock, B.H.; Joseph, J.; Keegan, T.H.M.: Psychological distress and associated additional medical expenditure in adolescents and young adult cancer survivors.
3. Jawad, M.U.; Pollock, B.H.; Alvarez, E.; Carr-Ascher, J.R.; Randall, R.L.; Thorpe, S.W.: Non-private health insurance predicts advanced stage at presentation and amputation in lower extremity high grade bone sarcoma: A National Cancer Database Study
4. Pollock, B.H.; Bergheimer, C.L.; Nesbitt, T.S.; Stoltz, T.; Belafsky, S.; Burtis, K.C.: Healthy Davis Together: Creating a model for community control of COVID-19.
5. Dewa, C.; Che, Z.; Guggenbickler, A.M.; Phan, R.; Pollock, B.: Building a public health workforce for a university campus during a pandemic using a practicum framework: design and outcomes.
6. Schmidt, A.J.; Daza Torres, M.L.; Garcia, Y.E.; Ashby, J.L.; Pollock, B.H.; Sharpnack, J.; Nuno, M.: The impact of COVID-19 vaccination on California's return to normalcy.

7. Siembida, E.J.; Loomans-Kropp, H.A.; Tami-Maury, I.; Freyer, D.R.; Sung, L.; Crosswell, H.W.; Pollock, B.H.; Roth, M.E.: Variations in barriers and facilitators to adolescent and young adult clinical trial enrollment in community-based settings.
6. Papers in Preparation:
 1. Abdelhadi, O.A.; Joseph, J.; Pollock, B.H.; Keegan, T.H.M.: Shared decision-making, medical expenditures, and health care utilization among adolescent and young adult cancer survivors.

Refereed Presentations

1. "Reduction of aflatoxin bioavailability with ACCS₁₀₀ in an exposed South Texas population," Sept. 28, 2015, American College of Epidemiology Annual Meeting, Atlanta, GA.
2. "Case-Control Study of Pediatric HIV-Related Malignancies," Third Annual Florida Epidemiology Meeting, July 25, 1997, Miami Beach, FL.
3. "Do Clinical Prediction Rules Really Mean What They Say?" Annual Meeting of the American Federation for Clinical Research, 1987, San Diego, CA.
4. "Is Diagnosis More Accurate Than Prognosis?" Annual Meeting of the American Heart Association, 1986, Anaheim, CA.
5. "Heuristic and Algorithmic Interpretation of Cardiac Stress Tests." Annual Meeting of the American Association of Medical Informatics, 1986, Los Angeles, CA.
6. "Accuracy of a Heuristic Computer Program for the Diagnosis of Coronary Artery Disease." Annual Meeting of the American Federation for Clinical Research, 1986, Washington, DC.
7. "How Difficult is it to Predict the Future?" Annual Meeting of the American Federation for Clinical Research, 1986, Washington, DC.
8. "Extent and Severity of Myocardial Hypoperfusion as Independent Indices of Prognosis." Annual Meeting of the American Heart Association, 1985, Dallas, TX.
9. "Prognostic Accuracy Depends On Both the Patient and the Test." Annual Meeting of the American Heart Association, 1985, Dallas, TX.
10. "Accurate Computer Assessment of Clinical Coronary Artery Disease." Annual Meeting of the Society for Medical Decision Making, 1982, Boston MA.

Invited Presentations

International

1. "The Process, The Opportunities, The Challenges of Research in the New Trauma Center," First Clinical Research in Emergency, Trauma and Critical Care Workshop, Hamad General Hospital, February 25, 2013, Doha, Qatar.

2. “From Bench-to-Bedside and Back: Clinical Translational Trauma Research,” First Qatar Surgical Society Symposium and Third Annual Advanced Trauma Life Support (ATLS) for Middle East and North Africa (MENA) Conference, Hamad General Hospital, February 27, 2013, Doha, Qatar.
3. “Research Infrastructure to Support Emergency Department/Trauma Research: Data Operations,” First Qatar Surgical Society Symposium and Third Annual Advanced Trauma Life Support (ATLS) for Middle East and North Africa (MENA) Conference, Hamad General Hospital, February 27, 2013, Doha, Qatar.
4. “Registration/Classification, International Working Group on Adolescents, Teenagers and Young Adults,” Society for International Pediatric Oncology, Annual Meeting, Oct. 5, 2008, Berlin, Germany.
5. “Registration and Classification of Adolescent and Young Adult Malignancies,” International Working Group (IWG) on Adolescent and Young Adult (AYA) Oncology, Society for International Pediatric Oncology, Annual Meeting, Sept. 21, 2006, Geneva, Switzerland.
6. “Etiologic Factors for HIV-Associated Pediatric Malignancies,” Texas-United Kingdom Collaborative Research Initiative: Molecular Signature of Cancer—Bench to Clinic and Back Again Symposium, January 12, 2006, Oxford University, Oxford, England.
7. “The Re-Mission Project and Study: Intervention Trial to Increase Adherence for Adolescents and Young Adults with Cancer,” Pediatric Oncology Group of Ontario Multi-Disciplinary Symposium on Childhood Cancer: Supportive Care in Pediatric Oncology—Beyond Cancer Treatment. November 18, 2005, Toronto, Ontario, Canada.
8. Keynote Speaker, Texas-United Kingdom Collaborative Research Initiative: Computational Biology Workshop. “Clinical Need for Bioinformatics and Computational Biology,” July 31, 2004, Glasgow, Scotland, United Kingdom.
9. Keynote Speaker, National Arab American Medical Association (NAAMA) Symposium “Reaching Consensus on Practice Guidelines for Pediatric Oncology in Egypt: Establishment of Egyptian Pediatric Oncology Group,” January 11–18, 2004, Nasser Institute, Cairo, Egypt.
10. “Prognostic Significance of Early Detection of Childhood Cancer,” Visiting Professor, Department of Pediatrics, University of Calgary, June 12–13, 1997, Calgary, Alberta, Canada.
11. Visiting Professor in Oncology, “HIV-Related Malignancies in Children,” April 28–30, 1997. McGill University, and University of Montreal, Montreal, Quebec, Canada.
12. “Answering Clinical Questions: Clinical Trials in Bone Marrow Transplantation,” International Bone Marrow Transplant Registry Annual Meeting, January 24, 1995, Keystone, CO.
13. Visiting Professor, “Epidemiology in the Pediatric Oncology Group,” December 7, 1994, Rambam Medical Center, Haifa, Israel.

National/Regional

1. Distinctly UC Davis: Innovative Solutions to the COVID-19, Pandemic Plugged In Event Series: Sustaining Healthier Communities, “Healthy Davis Together,” June 23, 2021, virtual
2. “Integrative Testing Solutions,” The Back to School Conference: Safely Opening Classrooms in 2021, April 13, 2021, Las Vegas, NV (and virtual)
3. “The Role of Public Health in Preparing for the Next Pandemic,” National Public Health Week Symposium: UC Davis, April 9, 2021, virtual
4. “Creating a Model for Community Control of COVID-19.” Health Services Committee of the University of California Board of Regents, April 6, 2021, virtual
5. Deloitte COVID-19 Webinars: Leading the Path Forward, “The role of public and private partnerships in recovery,” March 11, 2021, virtual
6. “Association of Clinical and Translational Science Mock Study Section 2021,” March 30, 2021, Mock Study Section Chair, virtual
7. “Environmental Factors and Hepatocellular Carcinoma,” October 17, 2020, Texas Collaborative Center for Hepatocellular Cancer (TeCH) Annual Symposium, virtual
8. “Launch of *Healthy Davis Together* Initiative,” September 17, 2020, State to State Sharing: Lessons Learned in Planning for IHE, COVID-19 Response Community of Practice Webinar, Centers for Disease Control and Prevention, virtual
9. “California Institutions of Higher Education COVID-19 Preparations,” September 24, 2020, State to State Sharing: Lessons Learned in Planning for IHE, COVID-19 Response Community of Practice Webinar, Centers for Disease Control and Prevention, virtual
10. “Epidemiology and Public Health in the Era of the COVID-19 Pandemic,” UC Davis Department of Pathology and Laboratory Medicine Grand Rounds, June 17, 2020, Sacramento, CA
11. “COVID-19 in Sacramento,” The Research and Education Community Advisory Board, UC Davis Clinical Translational Science Center Science Café, April 30, 2020, Sacramento, CA
12. “Data Quality in Outcome Assessments: Panel 3,” September 23, 2019, The Forum for Collaborative Research/Berkeley Public Health, *Rare Diseases Forum Workshop*, National Press Club, Washington, DC
13. “Liver Cancer Prevention Strategies in the U.S.,” April 16, 2019, Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, TX
14. “Liver Cancer Risk in a Vulnerable South Texas Population,” Department of Epidemiology, University of Florida College of Public Health and Health Professions, January 31, 2019, Gainesville, FL
15. “Liver Cancer Epidemiology: Risk Factors Beyond Cirrhosis,” University of California Davis 4th Annual Liver Research Day, October 24, 2018, Davis, CA

16. “Careers in Public Health,” 2018 UC Davis Pre-Health Conference, October 6, 2018, Davis, CA
17. “Designing Clinical Trials in the Children’s Oncology Group (COG): Special Considerations for Lifestyle Intervention Trials,” COG State-of-the-Science Nutrition Meeting, October 1, 2018, Dallas, TX
18. “Health Transitions into Adulthood: Growing up with Chronic Diseases of Childhood,” In *Health Transitions into Adulthood: Growing up with Chronic Diseases of Childhood* (Moderator: Pollock), September 25, 2018, 2018 American College of Epidemiology Annual Meeting, Cincinnati, OH
19. “Design Considerations for Adult Emergency/Trauma Research: Parts 1 and 2,” Emergency Clinical Research Symposium, Society for Clinical Research Associates, June 7, 2018, Chicago, IL
20. “Data Science: A New Team Sport?” Society for Clinical Research Associates Northern California Chapter, May 17, 2018, Sacramento, CA
21. “Future of Public Health Panel,” San Diego State University Graduate Student Council Event, San Diego State University, March 20, 2018, San Diego, CA
22. “Putting Public Health Preparedness into Practice—Lessons Learned from Natural Disasters: California Wildfires,” Association of Schools & Programs of Public Health Annual Meeting, March 8, 2018, Washington, DC
23. “Biostatistics as a Team Sport in Clinical and Translational Research,” Division of Public Health Sciences, Wake Forest School of Medicine, October 31, 2017, Winston-Salem, NC
24. “Study Design Challenges: Why Is It So Hard to Do Integrative Therapies Research?” Society for Clinical Research Associates 26th Annual Conference, October 7, 2017, Orlando, FL
25. “Lifestyle and clinical correlates of hepatocellular carcinoma in South Texas: A matched case-control study,” University of California Davis Comprehensive Cancer Center Symposium, September 28, 2017, Sacramento, CA
26. “Enhancing Interactions Between Biostatisticians and Other Disciplines in the Clinical and Translational Team Science,” University of Kansas Medical Center, *Department of Biostatistics Symposium Contemporary Statistical Issues in Medical/Health Related Research*, June 23, 2017, Kansas City, KS
27. “Zika Virus and Other Public Health Crises,” The Research and Education Community Advisory Board, UC Davis Clinical Translational Science Center Science Café, January 26, 2017, Sacramento, CA
28. “Mitigating Liver Cancer Risk in An Underserved Community,” University of California Merced, September 20, 2016, Merced, CA
29. “Public Health Sciences at UC Davis,” Research and Education Community Advisory Board (RECAB), UC Davis, September 21, 2016, Sacramento, CA
30. “Epidemiology in Transition,” Epidemiology Congress of the Americas 2016, June 22, 2016, Miami, FL
31. “Pathology and Public Health: Inseparable or Never the Twain Will Meet?” Department of Pathology, University of California, Davis, April 18, 2016, Sacramento, CA

32. "Pediatric Cancer Care Delivery Research" Cincinnati Children's Hospital, February 25, 2016, Cincinnati, OH
33. "Infusion of Clinical / Health Informatics into Epidemiology," 1st Epidemiology Forum, California Department of Public Health, January 28, 2016, Sacramento, CA
34. "Public Health Sciences and Informatics: A Marriage Made in Heaven?" Department of Epidemiology and Biostatistics, University of California, San Francisco, December 4, 2015, San Francisco, CA
35. "Radiology and Public Health," UC Davis Department of Radiology Grand Rounds, October 9, 2015, Sacramento, CA.
36. "Etiology of HCC in Minority Populations," UC Davis 1st Annual Liver Research Day, October 14, 2015, Davis, CA.
37. "Workshop: Research in Public Health," 13th Annual UC Davis Pre-Medical and Pre-Health Professions National Conference, October 11, 2015, Davis, CA.
38. "UC Davis Department of Public Health Sciences," Sacramento Latino Medical Association, July 21, 2015, Sacramento, CA
39. "Funding Multidisciplinary Research Teams," Center of Expertise on Migration and Health Research Meeting: Logistics, May 8, 2015, Davis, CA
40. "Preventing Disease and Shaping Health Policy," Center for Information Technology Research in the Interest of Society (CITRIS), April 8, 2015, UC Berkeley, Berkeley, CA
41. "Understanding How Health Happens Where You Live: Importance of Place," UC Davis Center for Reducing Health Disparities, April 6, 2015, Sacramento, CA
42. "The Interface Between Biostatistics and Data Management," Association of Clinical and Translational Statisticians Annual Meeting, August 3, 2014, Boston, MA.
43. "A Transdisciplinary View of Clinical and Translational Research," Keynote Presentation, May 8, 2014, Texas Tech University Health Science Center, El Paso, TX
44. "Biostatistician's Perspective: Roles in Observational Studies, Electronic Health Records & Big Data," April 11, 2014, Translational Science 2014 Meeting, Association for Clinical and Translational Science (ACTS) and American Federation for Medical Research (AFMR), Washington, DC
45. "The Burden of Liver Cancer in South Texas," March 18, 2014, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
46. "Cancer Care Delivery Research: Pediatric Perspective," March 17, 2014, Division of Pediatric Hematology, Oncology, and Stem Cell Transplant, Department of Pediatrics, Columbia University Medical Center, New York, NY.
47. "Integration of Public Health and Informatics in Clinical and Translational Research," October 31, 2013, University of Texas Medical Branch, Galveston, TX "

48. Integrating Biological Markers into Clinical Research and Translational Study Designs," Association of Clinical and Translational Statisticians Annual Meeting, August 4, 2013, Montreal, Quebec, Canada.
49. "Expanding the Role of Epidemiologists in Clinical Translational Research," September 23, 2013, American College of Epidemiology (ACE) 2013 Annual Meeting, Louisville, KY
50. "Multidisciplinary Data Operations Approach for Clinical/Translational Research," May 17, 2013, University of Cincinnati Medical Center, Center for Clinical and Translation and Science and Training (CCTST) Grand Rounds, Cincinnati, OH
51. "Integrating Biological Markers into Clinical Research Study Design: A Biomarker is a Biomarker..." April 18, 2013, *Translational Science 2013 Meeting*, Association of Clinical Translational Science, Washington, DC
52. "Reproducible Research: Selecting Data Operations Tools," March 11, 2013, Eastern North American Region (ENAR), International Biometric Society, Orlando, FL
53. "Primary Liver Cancer in San Antonio: From Clusters to Interventions," January 7, 2013, University of California at Irvine, Irvine, CA
54. Hepatocellular Carcinoma in South Texas: An Epidemic?" November 14, 2012, College of Public Health, University of Nebraska Medical Center, Omaha, NB
55. "Epidemiology of Adolescent and Young Adult Cancers in Texas" October 12, 2012, University of Texas Health Center at Tyler, Tyler, TX
56. "Data Management for Clinical Translational Research: A Multidisciplinary Perspective," Greater San Antonio Society of Clinical Research Associates Chapter, August, 24, 2012, San Antonio, TX
57. "Database Approaches for Clinical Translational Research, Annual Association of Clinical Translational Statisticians Meeting, July 28, 2012, San Diego, CA.
58. "The Epidemiology of Adolescent and Young Adult Cancers in Texas," 2nd Annual Texas Adolescent and Young Adult (TAYA) Oncology Conference 2012, March 3, 2012, San Antonio, TX
59. "Informatics Needs and Challenges in Cancer Research: The Perspective from Clinical Translational Researchers," National Cancer Policy Forum Workshop, February 27, 2012, Institute of Medicine, Washington, DC
60. "The Biostatistician's Role in Managing Clinical Translational Research Data," The Harvard Catalyst Biostatistics Program Seminar, March 30, 2011, Harvard University, Boston, MA
61. "The Human Studies Database Project," Annual Meeting of the Association for Clinical Translational Statisticians, August 1, 2010, Vancouver, BC, Canada
62. "Serious Gaming: More Than Fun and Entertainment, Statistical Education," 2009 Southern Regional Council in Statistics (SRCOS), June 10, 2009, Jekyll Island, GA
63. "Cancer in Children and Adolescents in Texas: A Unique Population?" Genetics & Biology of Childhood Cancer 2009: Traveling the Road of Childhood Cancer, From Cause to Cure, Feb. 26, 2009, San Antonio, TX

64. "The Dynamics of Treating Patients in 'The Gap' (18 to 30 Year Olds)," Fourth Annual Oncology Congress, Sept. 26, 2008, San Francisco, CA
65. "Outcome Disparities for Adolescents and Young Adults with Cancer," Division of Pediatrics, University of Texas M.D. Anderson Cancer Center, May 18, 2008, Houston, TX
66. "Future of the Association of General Clinical Research Center Statisticians," 2007 Annual Meeting, July 28, 2007, Salt Lake City, UT
67. "Cancer in Adolescents and Young Adults: A Special Population," Nevada Cancer Institute, December 19, 2006, Las Vegas, NV
68. "Complementary and Alternative Medicine Studies in Pediatric Oncology," Nutritional Intervention and Complementary Medicine from the Laboratory to the Community: Cancer Prevention, Diagnosis, and Treatment, San Antonio Cancer Institute, January 6, 2006, San Antonio, TX
69. "Multi-Institution Collaborative Research Coordinated by University of Texas Health Science Center at San Antonio," Bio Texas Summit 2005, June 8, 2005, Austin, TX
70. "Access to Care for Children with Cancer in Texas," Pediatric Hematology/Oncology Grand Rounds, Cook Children's Hospital, May 27, 2005, Ft. Worth, TX
71. "Conducting Etiologic Research in Cancer Cooperative Groups: Pediatric HIV-Related Malignancies," Roswell Park Cancer Institute, March 25, 2005, Buffalo, NY
72. "Approaches to Epidemiologic Studies for Lupus and Related Disorders," Keynote Presentation, Consensus Conference on the Epidemiology of Lupus and Related Disorders, Lupus Foundation of America, May 20, 2005, Arlington, VA.
73. "Phase III Study of Thiol Chemoprotection," Eleventh Annual Neuro-Oncology and Blood-Brain Barrier Consortium Meeting, March 19, 2005, Portland, OR
74. "New Frontiers in Translational Research in Neuro-Oncology and the Blood-Brain Barrier: Outcomes in Glioma, Statistics," Tenth Annual Neuro-Oncology and Blood-Brain Barrier Consortium Meeting, Bend, OR, March 20, 2004
75. "Re-Mission as a Research Project," 2004 HopeLab Research Retreat, February 20-21, 2004, Laguna, CA
76. "Design of Clinical Interventions," Workshop Session, Southern Society for Clinical Investigation, Southern Society for Pediatric Research, February 12-14, 2004, New Orleans, LA
77. "Issues of Adolescents and Young Adults with Cancer," 2003 HopeLab Research Retreat, December 11, 2003, Palo Alto, CA
78. "New Advances in Oncology Practice," Grand Rapids Clinical Oncology 8th Annual Distinguished Lecture Series, November 14, 2003, Grand Rapids, MI.
79. "Long Term Survivorship in Childhood Cancer," 8th Annual Bits and Pieces of Pediatric Oncology Nursing Conference, May 17, 2003, CHRISTUS Santa Rosa Children's Hospital, San Antonio, TX

80. "Lessons Learned from Conducting Cancer Control Research in Children: Implications for Adult Oncology," Spring 2003 Southwest Oncology Group Meeting, April 9–13, 2003, San Diego, CA
81. "Statistics for Clinicians," Drug Development Lecture series, April 2, 2003, The Institute for Drug Development, San Antonio, TX
82. "How to Find and Evaluate a Clinical Trial," Third Annual Symposium Clinical Trials: Benefits and Barriers, March 1, 2003, Clinical Trials Task Force and the University of Texas Health Science Center at San Antonio School of Nursing, San Antonio, TX
83. "Epidemiology of Prostate Cancer: Clues to Disease Prevention," First International Conference on Chemoprevention of Prostate Cancer, March 7, 2003, The University of Texas Health Science Center at San Antonio, San Antonio, TX
84. "Children to Adults: Implications for Cancer Prevention," 12th Annual Symposium on Cancer Research, July 12, 2002, San Antonio Cancer Institute, San Antonio, TX
85. "Cancer Control Research in the Children's Oncology Group," Grand Rounds, May 7, 2001. Department of Pediatrics, University of Texas Southwestern, Dallas, TX
86. "A National Childhood Cancer Control Research Agenda," August 22, 2000. University of Texas Health Science Center at San Antonio, San Antonio, TX
87. "Building Data Capacity: Resources for Public Health Research," Panel Discussant, August 4, 2000. 6th Annual Florida Epidemiology Meeting. Gainesville, FL
88. "Neuroblastomas and Childhood Cancer," May 25, 2000, Florida Environmental Health Association 52nd Annual Meeting, Tampa, FL
89. "Self-Care Intervention Research and Application to Pediatric Oncology," February 24, 2000, Pediatric Oncology Nursing State of the Science National Summit, Natcher Auditorium, National Institutes of Health Campus, Bethesda, MD
90. "Studying Environmental Exposures Among Children with Cancer: Current Technologies, Methodological Challenges, and Community Concerns," Biomarker Panel Discussant, January 25–27, 2000, Atlanta, GA
91. "Childhood Cancer: Causes and Control," November 7, 1999, *Families Can Survive* Workshop; Sponsored by the Hawaii Chapter of the American Cancer Society, Honolulu, HI
92. "Early Detection of Childhood Cancer," November 5, 1999, University of Hawaii Cancer Research Center, Honolulu, HI
93. "Cancer Epidemiology at the University of Florida," First Annual Symposium, Epidemiology and Public Health Research in Florida: Current Work and Anticipated Needs, 1995, Gainesville, FL
94. "Pharmacogenetics and White, Black and Hispanic Differences in Childhood Acute Lymphoblastic Leukemia," May 8, 1997, Baylor College of Medicine, Houston, TX

95. "Pediatric HIV-Related Malignancies," April 30, 1997, Oncology Grand Rounds, McGill University, Montreal, Quebec, Canada
96. "Why Study Medical Outcomes in Pediatric Oncology?" October 30, 1995; Pediatric Oncology Group Meeting, Chicago, IL
97. "Evaluating Quality of Life in 'Different Populations' for Patients with Cancer," March 2, 1995; National Cancer Institute 2nd National Conference on Quality-of-Life Assessment for Cancer; Bethesda, MD
98. "Race Differences in the Survival of Childhood Acute Lymphoblastic Leukemia," Yale University Medical Oncology Grand Rounds, May 10, 1994, New Haven, CT
99. "Differences in the Survival on Childhood Cancer by Race/Ethnicity." Tulane School of Public Health & Tropical Medicine, January 28, 1994, New Orleans, LA
100. "Epidemiology of Childhood Cancers," Krinsky Memorial Lecture, Wayne State University Department of Pediatrics, Grand Rounds, June, 1993, Detroit, MI
101. "Early Detection of Childhood Cancer: A Historical Cohort Analysis," Univ. of Texas, Southwestern, Department of Pediatrics, Grand Rounds, June 26, 1991, Dallas, TX
102. "Quality Assurance for Interventions in Clinical Trials: Data Monitoring, Data Management, and Statistical Analysis"; November 4, 1993; American Cancer Society National Conference on Clinical Trials; Atlanta, GA

B. Areas of Research Interest:

Cancer epidemiology
Cancer prevention and control
Cancer care delivery research
Biostatistics
Clinical trials
Health informatics
Health services research
Clinical and translational research infrastructure
Pediatric oncology
Medical oncology

C. Current Projects:

- i. *Healthy Davis Together* comprehensive community intervention to reduce COVID-19 spread in Davis, California
- ii. Prospective cohort study of health care workers to determine the role of COVID-19 serologies for surveillance.
- iii. Long-term outcomes for U.S. service members who participated in Operation Enduring Freedom (OEF) or Operation Iraqi Freedom (OIF) who sustained genitourinary injuries

D. Research Support (Grants and Contracts):

Source: University of California Office of the President, (R00RG3037, Pollock)
Title: **Prospective Cohort Study of Health Care Workers to Determine Natural History of COVID-19 Infection**

Period: 5/20–4/21

Directs: \$25,000

Role: Principal Investigator

Status: Active

Source: National Cancer Institute, NIH (UG1 CA189955, Pollock)

Title: **Children's Oncology Group NCI Community Oncology Research Program (NCORP) Research Base**

Period: 7/19–6/25

Directs: \$28,553,882

Role: Principal Investigator

Status: Active

Source: Department of Defense (W81XWH-16-2-0013, Log 14027001)

Title: **Trauma Outcomes and UroGenital Health in OEF/OIF (TOUGH)—A Retrospective Cohort Study with Long-Term Follow-up Project**

Period: 7/16–6/21

Directs: \$3,394,735

Role: Principal Investigator

Status: Active

Source: National Center for Advancing Translational Sciences, NIH (UL1TR000002, Berglund)

Title: **UC Davis Clinical and Translational Science Center**

Period: 7/16-6/21

Directs: \$13,547,270

Role: Co-Investigator

Status: Active

Source: National Cancer Institute, NIH, (R01CA201788, Pollock/Ladas/Bhatia)

Title: **Probiotics for Prevention of Acute Graft-vs-Host Disease in Children with Cancer**

Period: 9/16-7/21

Directs: \$2,097,580

Role: Principal Investigator/MPI

Status: Active

Source: Patient Center Outcomes Research Institute (PCORI), subcontract from Kansas University Medical School (CDRN-1306-04631 PHASE II)

Title: **Greater Plains Collaborative Clinical Data Research Institute, Phase II**

Period: 7/15-9/18

Directs: \$24,207 (subcontract)

Role: Site PI

Status: Active

Source: Solano County (Aguilar-Gaxiola)

Title: **Mental Health Interdisciplinary Collaboration and Cultural Transformation**

Model

Period: 1/16-12/20
Directs: \$521,739
Role: Co-Investigator
Status: Active

Source: National Cancer Institute, NIH (UG1 CA189955, Pollock)
Title: **Children's Oncology Group NCI Community Oncology Research Program (NCORP) Research Base**

Period: 9/14–8/19
Directs: \$19,806,175
Role: Principal Investigator
Status: Active

Source: National Cancer Institute, NIH (P30 CA093373, DeVere White)
Title: **UC Davis Comprehensive Cancer Center**

Period: 7/16–6/21
Directs: \$1,901,554
Role: Program Leader (Program 4: Population Sciences and Health Disparities)
Status: Active

Source: Patient Centered Outcomes Research Institute (PCORI), subcontract from Kaiser Foundation Research Institute, PCS-1403,12653, Gould

Title: **Pragmatic trial of more versus less intensive strategies for active surveillance of patients with small pulmonary nodules: the Lung Nodule Surveillance Trial (LNST)**

Period: 8/15-6/17
Directs: \$1,675,977 (subcontract)
Role: Co-Investigator
Status: Completed

Source: Patient-Centered Outcomes Research Institute (PCORI)

Title: **Greater Plains Collaborative-Clinical Data Research Network**

Period: 1/14–6/15
Directs: \$505,300
Role: Site PI (San Antonio Site), and Methods Core Director for Consortium
Status: Completed

Source: National Cancer Institute, NIH (P30 CA054174-19S5, Thompson)

Title: **Cancer Therapy & Research Center–Experimental Therapeutics**

Period: 4/14–3/15
Directs: \$47,352
Role: Core Director
Status: Completed

Source: National Cancer Institute, NIH (U10 CA095861)

Title: **Children's Oncology Group as a Community Clinical Oncology Group (CCOP) Research Base**

Period: 6/13–7/14
Directs: \$4,855,003
Role: Principal Investigator
Status: Completed

- Source: Institute for the Integration of Medicine and Science, Pilot Project from Clinical Translational Science Award, National Center for Advancing Translational Sciences, NIH (UL1 TR001120, Clark)
Title: **Assessment of Risk Factors for Hepatocellular Carcinoma in the San Antonio Biomarkers of Risk for Prostate Cancer (SABOR) Population**
Period: 12/13–11/14
Directs: \$25,000
Role: Principal Investigator
Status: Completed
- Source: National Center for Advancing Translational Sciences, NIH (UL1 TR001120, Clark)
Title: **Institute for Integration of Medicine & Science: A Partnership to Improve Health**
Period: 9/13–4/18
Directs: \$ 19,538,715
Role: Director: Biostatistics, Epidemiology, Research Design Key Function Core; and Director, Biomedical Informatics Core
Status: Completed
- Source: National Center for Complementary & Alternative Medicine, NIH (R01 AT007448)
Title: **Oxidative Stress and Programmed Death Pathways: Cross Talk in Pancreatic Cancer**
Period: 9/12–6/17
Directs: \$970,000
Role: Co-Investigator
Status: Completed
- Source: National Cancer Institute, NIH (R21 CA161180, Wang)
Title: **Metformin, Statins, and Prostate Cancer in Type 2 Diabetes**
Period: 9/12–8/14
Directs: \$517,447
Role: Co-Investigator
Status: Completed
- Source: National Institute on Minority Health and Health Disparities, NIH (R01 MD005819)
Title: **Prevention of Hepatocellular Carcinoma in Vulnerable Communities in Texas**
Period: 3/12–6/13
Directs: \$1,033,074
Role: Principal Investigator (University of Texas Health Science Center at San Antonio Subcontract)
Status: Completed
- Source: Cancer Prevention Research Institute of Texas, Individual Investigator Award (RP120462)
Title: **Environmental Determinants of Hepatocellular Carcinoma in South Texas**
Period: 12/11–11/14
Directs: \$1,200,000
Role: Principal Investigator
Status: Completed

- Source: National Institute of Allergy & Infectious Diseases, NIH (HHSN272201000038I, Patterson)
Title: **Task A05: Small Animal Model Development and Utilization for Target Identification and Testing of Diagnostics, Therapeutics and Vaccines for Invasive Aspergillosis**
Period: 9/10–9/15
Directs: \$675,223
Role: Biostatistician
Status: Completed
- Source: National Institute of Allergy & Infectious Diseases, NIH (HHSN272201000038I, Patterson)
Title: **Task A13: Small Animal Model Development and Utilization for Target Identification and Testing of Diagnostics, Therapeutics and Vaccines for Selected Invasive Fungal Diseases**
Period: 3/10–9/15
Directs: \$957,433
Role: Biostatistician
Status: Completed
- Source: National Cancer Institute, NIH (P30 CA054174, Thompson)
Title: **Cancer Therapy & Research Center–Biostatistics and Informatics Shared Resource**
Period: 8/09–07/14
Directs: \$1,300,530
Role: Core Director
Status: Completed
- Source: National Cancer Institute, NIH (CA 139476, Giles)
Title: **Inhibition of Autophagy: A Novel Therapeutic Strategy for Advance Solid Tumors**
Period: 7/09–06/11
Directs: \$333,347
Role: Co-Investigator
Status: Completed
- Source: National Cancer Institute, NIH (U10 CA095861)
Title: **Children’s Oncology Group as a Community Clinical Oncology Group (CCOP) Research Base**
Period: 6/07–5/12
Directs: \$11,259,171
Role: Principal Investigator
Status: Completed
- Source: USAAMRAA (W81XWH-08-2-0109, Peterson)
Title: **Strong Star Multidisciplinary PTSD Research Consortium**
Period: 06/08–02/13
Directs: \$12,586,155
Role: Co-Investigator
Status: Completed

- Source: National Institute for Child Health and Human Development, NIH (U10 HD055942-01, Brzyski)
Title: **Cooperative Multicenter Reproductive Medicine Network**
Period: 09/07–07/12
Directs: \$292,000
Role: Co-Investigator
Status: Completed
- Source: National Institute for Child Health and Human Development, NIH (HHSN267200700006C, Hale)
Title: **National Children's Study (NCS)**
Period: 09/07–07/12
Directs: \$25,216,292
Role: Co-Investigator (Epidemiology Director)
Status: Completed
- Source: National Center for Research Resources, NIH (UL1 RR025767, Clark)
Title: **Institute for Integration of Medicine & Science: A Partnership to Improve Health**
Period: 5/08–9/13
Directs: \$20,332,750
Role: Director: Biostatistics, Epidemiology, Research Design Key Function Core; and Director, Biomedical Informatics Core
Status: Completed
- Source: National Cancer Institute, NIH (R01 CA131039, Bao)
Title: **Image-Guided Interventional Cancer Therapy with Liposomal Radionuclides**
Period: 09/08–08/11
Directs: \$462,672
Role: Co-Investigator
Status: Completed
- Source: Federal Drug Administration (R01 FD003118, Curiel)
Title: **A phase II trial on Ontak to Treat Refractory Epithelial Ovarian Carcinoma under BB-IND12345**
Period: 03/06–02/10
Directs: \$375,000
Role: Co-Investigator
Status: Completed
- Source: National Institute of Health, NINDS (R01 NS050627, Brey)
Title: **Cognitive Function in SLE (COGNITION)**
Period: 04/06–03/11
Directs: \$4,975,814
Role: Co-Investigator
Status: Completed
- Source: University of Texas System
Title: **University of Texas Health Science Center at San Antonio (UTHSCSA) and University of Texas San Antonio (UTSA) Bioinformatics/Computational Biology Program**
Period: 1/05–12/07
Directs: \$2,200,000
Role: Principal Investigator
Status: Completed

Source: National Heart, Lung and Blood Institute, NIH (K30 HL004159, Lichtenstein)
Title: **University of Texas Health Science Center at San Antonio
Master Degree in Clinical Investigation**

Period: 09/05–4/08

Directs: \$287,996

Role: Co-Leader

Status: Completed

Source: National Institute of Mental Health (P20 MH068662, Bowden)

Title: **Bipolar Illness Intervention in Hispanic Communities**

Period: 08/04–04/09

Directs: \$1,692,279

Role: Co-Investigator

Status: Completed

Source: National Cancer Institute, NIH (R03 CA110788, Baillargeon)

Title: **Obesity in Hispanic Children with Leukemia**

Period: 07/04–06/05

Directs: \$100,000

Role: Senior Mentor

Status: Completed

Source: National Cancer Institute, NIH (R21 CA101717, Ramirez)

Title: **Increasing EPCT (Early Phase Clinical Trials) Accrual Among Hispanics in South
Texas**

Period: 09/03–08/05

Directs: \$646,060

Role: Co-Principal Investigator

Status: Completed

Source: National Cancer Institute, NIH (U10 CA095861)

Title: **Children's Oncology Group as a Community Clinical Oncology Group (CCOP)
Research Base**

Period: 6/02–5/07

Directs: \$9,338,233

Role: Principal Investigator

Status: Completed

Source: National Cancer Institute, NIH (P30 CA054174, Coltman)

Title: **San Antonio Cancer Institute/Cancer Therapy & Research Center**

Period: 8/02–07/09

Directs: \$1,489,605

Role: Biostatistics Core Director, and Associate Director for Cancer Prevention and Control

Status: Completed

Source: National Institutes of Dental and Craniofacial Research, NIH (R01 NS045186,
Hargreaves)

Title: **NPY Regulation of Peripheral Human Nociceptors and Pain**

Period: 12/02–11/07

Directs: \$2,740,416

Role: Co-Investigator

Status: Completed

Source: National Institute on Drug Abuse, NIH (P01 DA016719, Hargreaves)

Title: **Peripheral Mechanisms of Opioid Analgesia**

Period: 09/03–4/08

Directs: \$2,493,781

Role: Biostatistics Core Director

Status: Completed

Source: National Cancer Institute, NIH (U01 CA69853, Rowinsky)

Title: **Phase I Clinical Trials of Anticancer Agents**

Period: 02/03–01/08

Directs: \$3,560,479

Role: Co-Investigator

Status: Completed

Source: National Center for Research Resources, NIH (M01 RR001346, Mundy)

Title: **General Clinical Research Center: Biostatistics Core Supplement**

Period: 11/02–10/03

Directs: \$726,226

Role: Principal Investigator (Biostatistics Core)

Status: Completed

Source: National Heart, Lung and Blood Institute, NIH (K30 HL004159, Lichtenstein)

Title: **University of Texas Health Science Center at San Antonio—
Master Degree in Clinical Investigation**

Period: 09/00–8/05

Directs: \$1,355,737

Role: Co-Leader

Status: Completed

Source: Department of Veteran Affairs (NRI 98-183, Rittman)

Title: **Culturally Sensitive Models of Stroke Recovery and Caregiving After Discharge
Home**

Period: 10/00–09/04

Directs: \$724,884

Role: Co-Investigator

Status: Completed

Source: Department of Health, State of Florida

Title: **Perinatal HIV Prevention Program in Florida**

Period: 07/00–06/01

Directs: \$238,095

Role: Co-Investigator

Status: Completed

Source: National Institutes for Mental Health (R01 MH060632, Eyberg)

Title: **Maintenance Treatments for Conduct-Disordered Children**

Period: 10/00–09/04

Directs: \$1,100,274

Role: Co-Investigator

Status: Completed

- Source: Department of Veteran Affairs Health Services Research & Development (NRI 98-182, Uphold)
Title: **Predictors of Outcomes in HIV-Infected Males**
Period: 09/00–08/05
Directs: \$250,000
Role: Co-Investigator, Senior Mentor
Status: Completed
- Source: U.S. Centers for Disease Control and Prevention
Title: **Pilot Project to Develop a National Childhood Cancer Registry**
Period: 09/99–08/00
Directs: \$10,000
Role: Principal Investigator (Sub-Contract to the California Cancer Surveillance System)
Status: Completed
- Source: National Institutes of Health (K30 HL004109, Limacher)
Title: **University of Florida Advanced Postgraduate Program in Clinical Investigation, K30 Clinical Research Curriculum Development Award**
Period: 06/99–05/04
Directs:
Role: Associate Director
Status: Completed
- Source: National Cancer Institute, NIH (U10 CA 30969-A)
Title: **HIV-Related Malignancies Supplement for the Pediatric Oncology Group**
Period: 09/98–12/98
Directs: \$20,000
Role: Principal Investigator
Status: Completed
- Source: National Cancer Institute, NIH (U10 CA 37379)
Title: **Pediatric Oncology Group as a Research Base for the Community Clinical Oncology Program**
Period: 06/97–05/02
Directs: \$2,089,651
Role: Principal Investigator
Status: Completed
- Source: National Cancer Institute, NIH (U10 CA 30969)
Title: **Epidemiology Committee for the Pediatric Oncology Group**
Period: 01/96–12/01
Directs: \$140,207
Role: Principal Investigator
Status: Completed
- Source: Electrical Power Research Institute, Palo Alto, CA
Title: **Role of Electromagnetic Fields in the Proportionate Morbidity of Childhood Leukemia**
Period: 01/96–12/00
Directs: \$185,760
Role: Principal Investigator
Status: Completed
- Source: National Institute for Dental Research, NIH (P20 DE012396, Heft)

Title: **Planning Grant for the University of Florida Orofacial Pain Center**
Period: 11/95–03/96
Directs: \$51,756
Role: Biostatistics Core Director
Status: Completed

Source: National Institute for Environmental Health Sciences, NIH (P42 ES07375, James)
Title: **Health Effects of Chlorinated Compounds—Epidemiology and Biometrics Core C**
Period: 05/95–04/00
Directs: \$212,278
Role: Core Director
Status: Completed

Source: Department of Health and Rehabilitative Services, State of Florida
Title: **Cancer Control Hospital Report: Evaluation of State Cancer Registry**
Period: 1/95–7/95
Directs: \$24,584
Role: Principal Investigator
Status: Completed

Source: National Cancer Institute, NIH (U10 CA 37379)
Title: **Pediatric Oncology Group Research Base for Community Clinical Oncology Program**
Period: 06/94–05/97
Directs: \$617,271
Role: Principal Investigator
Status: Completed

Source: National Cancer Institute, NIH (R03 CA059170)
Title: **Determinants of Access to Pediatric Cancer Care**
Period: 06/93–05/95
Directs: \$43,264
Role: Principal Investigator
Status: Completed

Source: National Institute for Diabetes and Digestive and Kidney Diseases, NIH (R01 DK045830, Rosenbloom)
Title: **Body Composition in IGF-I Treated GH-Receptor Deficiency**
Period: 12/92–11/96
Directs: \$1,089,572
Role: Co-Investigator

Source: National Cancer Institute, NIH (R01 CA056296)
Title: **Epidemiologic Study of Pediatric HIV-Related Lymphomas**
Period: 09/92–08/98
Directs: \$1,425,688
Role: Principal Investigator
Status: Completed

Source: National Cancer Institute, NIH (R01 CA057004)
Title: **Case-Control Study of Risk Factors for Neuroblastoma**
Period: 09/91–07/96
Directs: \$30,409 (subcontract)
Role: Principal Investigator

Status: Completed

Source: National Cancer Institute, NIH (R01 CA055507, Murphy)

Title: **Pediatric AIDS Lymphoma Network Statistical Office**

Period: 07/91–07/94

Directs: \$179,027

Role: Principal Investigator

Status: Completed

Source: National Cancer Institute, NIH (U10 CA037379, Krischer)

Title: **Pediatric Oncology Group Research Base for Community Clinical Oncology Programs**

Period: 9/83–5/94

Directs: \$874,215

Role: Co-Investigator

Status: Completed

Source: National Cancer Institute, NIH (U10 CA037379, Krischer)

Title: **Pediatric Oncology Group Statistical Office**

Period: 12/88–12/95

Directs: \$8,775,338

Role: Co-Investigator, Cooperative Group Statistician

Status: Completed

NIH eRA Commons: bhpollck

III. TEACHING

A. Classroom Instruction

Date	Course Title	Class/Lab	Role
2020	<i>SPH290: MPH Seminar, UC Davis</i>	Class	Instructor of Record
2020	<i>SPH214/298: Scientific Proposal Writing, UC Davis</i>	Class	Instructor of Record
2017–2020	<i>SPH 205AY: Epidemiology for Health Professionals, UC Davis</i>	Class	Instructor of Record
2016–2019	<i>SPH 298: The Environment: Epidemiology and Policy, UC Davis</i>	Class	Instructor of Record
2016–2019	<i>SPH 298: Cancer Prevention and Control, UC Davis</i>	Class	Instructor of Record
2016–2019	<i>EPI 206: Epidemiologic Study Design, UC Davis</i>	Class	Instructor of Record
2016–2020	<i>EPI290: Epidemiology Doctoral Seminar, UC Davis</i>	Class	Instructor of Record
2016–2020	<i>SPH 192: MEDLIFE Class, UC Davis</i>	Class	Instructor of Record
2015–2017	<i>EPI 205A: Principles of Epidemiology, UC Davis</i>	Class	Instructor of Record
2010–2013	<i>Evidence-Based Medicine Short Course (4-hour) for the Department of Pediatrics Fellowship Program, UTHSCSA</i>	Class	Director

2007–2014	<i>Introduction to Clinical Investigation</i> Course (2-week, 8 hours/day short course), UTHSCSA	Class	Director
2009	<i>STA 6973: Statistical Methods in Epidemiology</i> (University of Texas at San Antonio, College of Business)	Class	Director
2008, 2010	<i>STA 6973: Statistical Methods in Clinical Trials</i> , (University of Texas at San Antonio College of Business)	Class	Instructor
2002–2006	<i>MEDI 5072 and MED 6061: Biostatistics 1 & 2</i> , Master of Science in Clinical Investigation (12), UTHSCSA	Class	Instructor
2002–2008	<i>MEDI 5071 and MEDI 6060: Patient Oriented Clinical Research Methods 1 & 2</i> , Masters of Science in Clinical Investigation (12), UTHSCSA	Class	Instructor
2000	<i>Epidemiology Methods I</i> (3.0), University of Florida	Class	Director
1997–1998	<i>Clinical Epidemiology</i> (3.0), University of Florida	Class	Director
1997	<i>Statistics 6176: Introduction to Biostatistical Methods</i> (4.0), University of Florida	Class	Co-Director and Instructor
1996–1997	<i>Clinical Epidemiology & Evidence Based Medicine</i> (3.0), University of Florida College of Medicine	Class	Co-Director and Instructor
1995	<i>Science of Clinical Research</i> (2.0), University of Florida College of Medicine	Class	Co-Director and Instructor
1994	Short Course: <i>Clinical Epidemiology for MD/PhD Students</i> (0.0), University of Florida	Class	Director
1993	<i>Statistics 6176: Introduction to Biostatistical Methods</i> (4.0), University of Florida	Class	Co-Director and Instructor
1988–1989	<i>Introduction to Medical Research</i> (1.0), University of Florida	Class	Director and Instructor

UTHSCSA=University of Texas Health Science Center San Antonio

B. Instructional Activities:

2019 – present	Member, Executive Committee, Graduate Group in Clinical Research, University of California, Davis
2018 – present	Member, Admissions Committee, PhD in Public Health Sciences Program, University of California, Davis
2017 – 2019	Member, UC Davis Continuing Professional Education (Extension) Faculty Advisory Committee, University of California, Davis
2016 – present	Member, Executive Committee, Graduate Group in Health Informatics, University of California, Davis
2014 – present	Member, Executive Committee, Graduate Group in Biostatistics, University of California, Davis
2017 – present	Member, Educational Policy Committee, Graduate Group in Health Informatics, University of California, Davis
2017 – present	Member, Graduate Group in Public Health Sciences, University of California, Davis
2014 – 2018	Director of Record, Master of Public Health (MPH) Program, Department of Public Health Sciences, University of California, Davis

2014 – present	Member, Graduate Group in Epidemiology, University of California, Davis
2014 – 2019	Member, Written Qualifying Exam Committee, Graduate Group in Epidemiology, University of California, Davis
2009 – 2011	Subcommittee on Educational Programs Operational Efficiency/Budget Enhancement Task Force, University of Texas Health Science Center at San Antonio
2007 – 2009	Special Member, Graduate Council, University of Texas at San Antonio Graduate School
2005 – 2014	Pediatric Scholarship Oversight Committee, Fellowship Programs, Department of Pediatrics, University of Texas Health Science Center at San Antonio
2005 – 2006	Faculty Advisor for the Surgery Residency Journal Club, Department of Surgery, University of Texas Health Science Center at San Antonio
2002 – 2014	Committee on Graduate Studies (COGS), Master of Science in Clinical Investigation, Graduate School, University of Texas Health Science Center at San Antonio
2002 – 2008	Co-Director, K30 Clinical Research Fellowship Program, University of Texas Health Science Center at San Antonio
1999 – 2001	Program Co-Director and Director of Admissions, University of Florida Master in Public Health Joint Degree Program
1990 – 1995	Faculty Advisor for the Pediatric Residency Journal Club, Department of Pediatrics, University of Florida
1990 – 1995	Pediatric Science Day Faculty Committee, Department of Pediatrics, University of Florida
1988 – 1999	Biostatistics and epidemiology research instruction for Residents and Fellows, Department of Pediatrics, University of Florida

2. Other Teaching Activities:

- i. Short Course: “Design Considerations for Adult Emergency/Trauma Research – Part 1 and Part II,” Emergency Clinical Research Symposium, Society of Clinical Research Associates (SOCRA):

June 7, 2018	Chicago, IL
June 20, 2019	Boston, MA
- ii. Short Course: “Epidemiology and Biostatistics,” Society of Clinical Research Associates (SOCRA), Professional Educational Certification Program:

October 18, 2019	San Diego, CA
July 26, 2019	Chicago, IL
March 29, 2019	Orlando, FL
July 27, 2018	Denver, CO
March 9, 2018	Miami Beach, FL
October 27, 2017	San Antonio, TX
July 28, 2017	Chicago, IL
March 18, 2017	Philadelphia, PA

October 28, 2016	Chapel Hill, NC
July 28, 2016	San Francisco, CA
March 18, 2016	Philadelphia, PA
October 23, 2015	Scottsdale, AZ
July 24, 2015	Chicago, IL
March 27, 2015	Orlando, FL
October 24, 2014	San Diego, CA
March 28, 2014	Orlando, FL
October 18, 2013	Las Vegas, NV
July 26, 2013	Denver, CO
March 15, 2013	Philadelphia, PA
October 26, 2012	San Diego, CA
July 13, 2012	Chicago, IL
October 28, 2011	San Francisco, CA
July 15, 2011	Chicago, IL
March 11, 2011	Philadelphia, PA
October 29, 2010	Chicago, IL
July 30, 2010	Boston, MA
November 13, 2009	St. Louis, MO
July 31, 2009	Boston, MA
March 13, 2009	San Antonio, TX
November 7, 2008	Scottsdale, AZ
July 18, 2008	Chicago, IL
March 14, 2008	Fort Worth, Texas
July 13, 2007	Memphis, TN
November 10, 2006	Atlanta, GA
July 14, 2006	San Antonio, TX
November 17, 2005	Charlotte, NC
November 19, 2004	San Francisco, CA
June 18, 2004	Denver, CO
February 27, 2004	Philadelphia, PA
November 21, 2003	Newport Beach, CA
June 13, 2003	Chicago, IL
February 14, 2003	Orlando, FL
November 15, 2002	Newport Beach, CA
June 7, 2002	Vancouver, BC, Canada
February 22, 2002	Miami Beach, FL
November 9 2001	Houston, TX
November 12, 1999	Toronto, ON, Canada
June 10, 1998	Durham, NC
March 23, 1998	Louisville, KY
June 18, 1997	Durham, NC
September 20, 1996	Durham, NC
June 15, 1996	Durham, NC
June 18, 1995	Durham, NC

iii. Short Course: Epidemiology Methods with Applications to the Pharmaceutical Industry,
University of Florida Department of Statistics *Week of Short Courses*:

March 8 – 10, 2000	Orlando, FL
March 3 – 5, 1999	Orlando, FL
March 9 – 11, 1998	Orlando, FL

3. Media and Software Developed:

- i. Pollock, B.H., Diamond, G.A.: CADENZA IV: FORTRAN Program For Computer-Assisted Diagnosis and Evaluation of Coronary Artery Disease, 1981.

C. Masters' Theses and Ph.D. Dissertation Directed, Membership on Supervising Committees, and Postdoctoral Fellows Supervised:

Jane Querido, Ph.D. (member of Ph.D. supervising committee), *Oppositional Defiant Disorder Intervention in Project Head Start*. Department of Clinical and Health Psychology, College of Health Professions, 2000–2001.

Sam Moolasarn, Ph.D. (member of Ph.D. supervising committee) *Depressive Adverse Effects of Antihypertensive Drugs: A Comparison of Atenolol with Verapamil*, University of Florida College of Pharmacy, 2000.

Patrick Bradshaw, M.P.H., Ph.D. (primary graduate advisor, member of the M.P.H supervising committee), Department of Health Policy and Epidemiology, University of Florida, 2000–2001

Sean Cavanaugh, M.D. (member of Ph.D. supervising committee), *Establishing and Validating a PSA Response Metric to Evaluate the Impact of Image Guided Radiation Therapy for Prostate Cancer*, Department of Radiological Sciences and Department of Radiation Oncology, University of Texas Health Science Center at San Antonio, 2002–2005.

Moraima Guadalupe, Ph.D., M.S. (member of M.S. supervising committee), *Risk factors influencing antibody responses to Kaposi's Sarcoma-1 associated Herpesvirus 2 latent and lytic antigens in patients under antiretroviral therapy in South Texas*, 2009–2010.

Barbara Ercole, M.D., M.S. (member of M.S. supervising committee), *Constitutional Genetic Variation Associated with Prostate Cancer Progression*, University of Texas Health Science Center at San Antonio, 2010–2011.

Alma I. Martinez-Jimenez, Ph.D. (member of Ph.D. supervising committee) *Individual Determinants Associated with Fasting Glucose Levels and Environmental Factors Associated with Diabetes Prevalence*, Department of Demography, University of Texas at San Antonio, 2010–2011.

Kaveh Najibfard, D.M.D., M.S. Clinical Investigation (member of M.S. thesis committee), *Remineralization of Early Caries by NanoHydroxyapatite Dentifrice*, Department of Community Dentistry, University of Texas Health Science Center at San Antonio, 2009–2010.

Susanne Schmidt, Ph.D. (member of Ph.D. supervising committee) *Inequalities In Injury Risk in U.S. Adults: Socioeconomic Status, Health Behaviors, and Contextual Determinants of Injury Morbidity and Mortality*, Department of Demography, University of Texas at San Antonio, 2012–2013.

Saima Siddiqui, M.D. (member of M.S. supervising committee) *Generalist and Specialist Collaboration for Cancer Management*, University of Texas Health Science Center at San Antonio, 2013–2015.

Allison Grimes, M.D. (member of M.S. supervising committee) *Genetic Markers for Chemotherapy-Related Pancreatitis in Childhood ALL*, Department of Pediatrics, University of Texas Health Science Center at San Antonio, 2013–present.

Nicole Jaime, candidate (member of supervising Dr.P.H. committee, public health practicum supervisor) *Dietary Correlates of Aflatoxin Exposure in South Texas*, San Antonio Regional Campus, University of Texas School of Public Health, 2013–2014.

Nina Multak, M.S. (member of supervising Ph.D. committee) *The Impact of Cognition on Technology Mediated Clinical Decision Support in the Physician Assistant Population*. Drexel University, College of Computing and Informatics, 2014–2016.

Danielle Ewing Rodriguez, M.P.H., Ph.D. (major professor and supervising committee chair) *Disease occurrence of malignant and nonmalignant central nervous system tumors among children and adolescents in California*, University of California, Davis, Graduate Group in Epidemiology, 2016–2017.

Jesse Pry, M.P.H., Ph.D. (major professor and supervising committee chair) *Investigating Risk and prevalence of emerging non-communicable disease in the developing world*, University of California, Davis, Graduate Group in Epidemiology, 2016–2019.

A.K.M. Mahbulul Islam, M.S. (major professor) Barriers to access of appropriate treatment for hepatocellular carcinoma in California, 2019–present.

IV. SERVICE

A. Professional Affiliations

3. University and Other Professional Activities:

2021 – present	University of California Office of the President Systemwide Fall Capacity Planning Group
2020 – 2020	California Department of Public Health Working Group on Colleges and Universities
2020 – 2021	Member, UC Davis COVID Preparedness Advisory Team (CPAT)
2020 – 2021	Member, UC Davis Fall Planning Operational Workgroup
2020 – 2020	Member, UC Davis Fall 2020 Scenario Planning: Instruction Planning Focus Group
2020 – present	Chair, University of California Systemwide COVID-19 Public Health Workgroup
2020 – present	Member, University of California System Health Coordinating Committee Executive Group
2019 – present	Member, Governance & Nominations Committee, University of California Global Health Institute, University of California
2019 – present	Member, Master of Public Health External Advisory Committee,

	University of California San Diego
2014 – 2019	Co-Leader, Population Sciences and Health Disparities Research Program, UC Davis Comprehensive Cancer Center, University of California, Davis
2014 – 2016	Genomics Working Group, University of California, Davis
2014 –present	Member, University of California Davis School of Medicine Council of Chairs
2013	Member, School of Medicine Strategic Planning Advisory Research Committee, University of Texas Health Science Center at San Antonio
2011 – 2012	Member, School of Medicine Dean’s Executive Committee, University of Texas Health Science Center at San Antonio, University of Texas Health Science at San Antonio, San Antonio, TX
2003 – 2005	Member, Clinical Oncology Research Committee, San Antonio Cancer Institute
2002 – 2012	Member, Data Safety Monitoring Committee, Cancer Therapy & Research Center, University of Texas Health Science Center at San Antonio
2001 – 2008	Member, Protocol Review Committee, San Antonio Cancer Institute/Cancer Therapy & Research Center, University of Texas Health Science Center at San Antonio
1997 – 2000	Departmental Representative, University of Florida College of Medicine Faculty Council
1996 – 1997	Member, Scientific Advisory Board, University of Florida Tissue Bank, Inc.
1995	Member, University of Florida Health Science Center Task Force for the Development of Clinical Investigations
1995 – 1996	Member, University of Florida Center for International Health
1994 – 2001	Associate Director, Center for the Study of Childhood Cancer (Type III Center)
1994 – 1997	Associate Director for Epidemiology, Biostatistics and Cancer Control, University of Florida Cancer Center
1993 – 1997	Member, University of Florida Cancer Center Executive Committee
1993 – 1995	Search Committee for Chief, Division of Hematology/Oncology, Department of Pediatrics
1999 – 2001	Associate Director for Cancer Control, University of Florida Shands Cancer Center

2. Past and Current Positions and/or Offices held in Professional Organizations:

2021 – present	Member, Awards Committee, Association for Clinical and Translational Science (ACTS)
2020 – 2021	Chair, Association of Schools and Programs of Public Health (ASPPH) 2021 Leadership Retreat Planning Committee
2018 – 2019	Chair Emeritus, National Cancer Institute Cancer Care Delivery Research Steering Committee, NIH
2014 – 2017	Inaugural Co-Chair, National Cancer Institute Cancer Care Delivery Research Steering Committee, NIH
2014 – 2020	Co-Chair, Methods and Processes Domain Task Force, NIH Clinical Translational Science Award National Consortium
2015 – 2019	President, Council of Epidemiology Chairs
2014 – present	Primary Representative for UC Davis, Association of Schools and Programs of Public Health (ASPPH)
2014 – 2015	Co-Chair, PCORnet Clinical Trials Task Force, Patient-Centered Outcomes Research Institute (PCORI)
2014 – 2015	Immediate Past President, Association of Clinical and Translational Statisticians
2013 – 2019	Member, National Conference of Lawyers and Scientists Standing Committee, American Association for the Advancement of Science and American Bar Association
2012 – 2013	President, Association of Clinical and Translational Statisticians
2012 – 2013	Chair, Biostatistics, Epidemiology, Research Design (BERD) Key Function Committee, Clinical Translational Science Award (CTSA) National Consortium
2011 – 2012	Vice Chair and Chair-Elect, Biostatistics, Epidemiology, Research Design (BERD) Key Function Committee, Clinical Translational Science Award (CTSA) National Consortium
2010 – 2014	Chairman, Advisory Committee for the Canadian Task Force on Adolescent and Young Adult Cancer
2008 – 2010	Chairman, Advisory Committee for the Texas Cancer Registry
2004 – 2014	Vice Chair, Children’s Oncology Group Community Clinical Oncology Program (CCOP) Subcommittee
2005 – 2008	Chair, Children’s Oncology Group Adolescent and Young Adult Cancer Control Subcommittee
2001 – 2004	Chair, Nominating Committee, Children’s Oncology Group
2000 – 2003	Chair, Children’s Oncology Group Cancer Control Committee
1994 – 2000	Chair, Pediatric Oncology Group Cancer Control Committee
1991 – 2000	Chair, Pediatric Oncology Group Epidemiology Committee

1990 – 1993 Vice Chair, Pediatric Oncology Group Early Detection and Prevention Subcommittee (of the Cancer Control Committee)

3. Other Professional Activities

2020 Member, Scientific Advisory Committee, Division of Biostatistics and Epidemiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

2018 – 2021 Chair, Publication Committee, A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis (APPLES), LEO Pharma.

2018 External Reviewer, Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, TX

2016 – 2018 Member, Scientific Review Committee, Scalable Collaborative Infrastructure for a Learning Healthcare System (SCILHS), Harvard University, Boston, MA

2016 – present Board Member, University of California Global Health Institute, University of California System

2015 Member, Planning Committee, *West Coast Health Systems Transformation Meeting*, May 12, 2015, American College of Preventive Medicine, Sacramento, CA

2015 Member, Society for Epidemiologic Research Annual Meeting, Abstract Review Committee

2014 – 2019 Member, External Advisory Committee, University of Texas Southwestern Medical Center, Center for Translational Medicine, Dallas, TX

2014 Reviewer, Florida Department of Health, James and Esther King Biomedical Research Program Grant Review Committee, Miami, FL

2014 Member, Scientific Advisory Committee, Division of Biostatistics and Epidemiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH

2013 – 2018 Chair, Data Safety Monitoring Board, A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis (APPLES), LEO Pharma.

2013 – 2020 Member, External Advisory Committee, University of Wisconsin Clinical Institute for Clinical and Translational Research, Madison, WI

2013 – 2014 Reviewer, C¹⁷ Research Network (Canadian Centres Battling Cancer and Blood Disorders in Children) Grant Program

2012 – 2020 Member, External Advisory Board, University of Florida Clinical and Translational Science Institute, Gainesville, FL

2012 – 2014 Member, Scientific Advisory Committee (SAC), CureSearch for Children’s Cancer

2011 – 2014	Member, Advisory Committee on Childhood Cancer, Cancer Prevention Research Institute of Texas (CPRIT)
2011 – 2012	Member, Planning Committee, <i>Informatics Needs and Challenges in Cancer Research</i> , National Cancer Policy Forum Workshop, Institute of Medicine
2009 – 2013	Member, Biostatistics, Epidemiology, Research Design (BERD) Key Function Committee Operations Group, Clinical Translational Science Award (CTSA) National Consortium
2010 – 2014	Member, External Advisory Council, Department of Electrical and Computer Engineering, College of Engineering, University of Texas at San Antonio
2009– present	Member, External Advisory Board, Department of Biostatistics, University of Kansas Medical Center
2008	Panel Member, National Institutes of Health, <i>Consensus Development Conference, Hydroxyurea: Treatment for Sickle Cell Disease</i> , Bethesda, MD January 29–30, 2008
2007 – 2017	Chair, Scientific Advisory Committee, A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis (APPLES), Astellas Pharma Inc. and LEO Pharma A/S
2005 – 2007	Faculty of 1000 Medicine, Pediatric Oncology Section
2005 – 2006	Member, Joint Planning Committee for Cooperative Programs in Public Health, San Antonio, Texas
2005 – 2008	Member, Texas Cancer Registry Data Work Group, Texas
2006	Co-Chair, Prevention/Cancer Control/Epidemiology/Risk Task Force, <i>National Cancer Institute Progress Review Group (PRG) on Adolescent and Young Adult Oncology</i> : Denver, CO, April 24–26, 2006.
2005	Member, <i>National Cancer Institute Progress Review Group (PRG) on Adolescent and Young Adult Oncology Planning Committee</i> , Austin, TX, December 6–7, 2005.
2004 – 2005	Member, <i>Task Force on the Future of Public Health in Texas</i> , University of Texas System
2004	Member, Texas Cancer Registry Funding Options <i>Ad Hoc</i> Work Group
2004 – 2005	Member, Executive Committee, San Antonio Life Science Institute (SALSI), University of Texas Health Science Center at San Antonio and University of Texas San Antonio
2002	Member, Planning Committee, National Institutes of Health <i>State-of-the-Science Conference on Symptom Management in Cancer: Pain, Depression and Fatigue</i> , July 15–17, 2002
1998 – 2001	Consultant, State of Florida Department of Health, Bureau of Environmental Epidemiology

1998 – 2001	Member, State of Florida Department of Health, Bureau of HIV/AIDS, Epidemiology Task Force
1995 – 1996	Member, State of Florida Department of Health Institutional Review Board for the Florida Cancer Data System (State Cancer Registry)
1992 – 1993	Member, Planning Committee, American Cancer Society National Conference on Clinical Trials

4. Professional and Scientific Organizations and Societies:

2014 – present	Fellow, American College of Epidemiology
2014 – present	Vice Chair, Children’s Oncology Group NCI Community Oncology Research Program (NCORP) Committee
2006 – present	Member, American Medical Informatics Association
2003 – 2006	Member, Committee on Women and Special Populations, Southwest Oncology Group
2003 – 2009	Member, Children’s Oncology Group Cancer Control Steering Committee
2000 – 2009	Member, Children’s Oncology Group Adolescent and Young Adult Steering Committee
2000 – 2004	Member, Medical and Scientific Advisory Board, National Childhood Cancer Foundation
1999 – 2004	Member, Nominating Committee, Children’s Oncology Group
1995 – 2000	Member, Advisory Committee, International Bone Marrow Transplant Registry
1994 – 2002	Member, Society for Pediatric Research
1993 – present	Member, American Statistical Association
1985 – present	Member, International Epidemiology Association
1985 – 2003	Member, Biometric Society
1980 – present	Member, American Public Health Association
1980 – present	Member, Society for Epidemiologic Research

B. Administrative Responsibilities:

1. Department, Division, Clinical Service, Coordinator, etc.:

2015 – present	Associate Dean for Public Health Sciences, School of Medicine, University of California Davis
2014 – present	Chair, Department of Public Health Sciences, School of Medicine, University of California Davis

2006 – 2014	Chair, Department of Epidemiology and Biostatistics, School of Medicine, University of Texas Health Science at San Antonio, San Antonio, TX
2001 – 2006	Director, Center for Epidemiology and Biostatistics, University of Texas Health Science at San Antonio, San Antonio, TX
1999 – 2001	Interim Chair, Department of Health Policy and Epidemiology, College of Medicine, University of Florida, Gainesville, FL
1999 – 2000	Vice Chair for Research, Department of Health Policy and Epidemiology, College of Medicine, University of Florida, Gainesville, FL
1999 – 2001	Director, Master in Public Health Joint Degree Program, College of Medicine, University of Florida, Gainesville, FL
1995 – 2001	Member, Executive Committee, University of Florida/Shands Cancer Center
1994 – 2001	Division Chief, Division of Epidemiology, Department of Health Policy and Epidemiology, College of Medicine, University of Florida, Gainesville, FL

V. OTHER PERTINENT INFORMATION:

Grant Reviewer:

Reviewer, CTSA Collaborative Innovation Awards Review, ZTR1 CI-4 National Institutes of Health, 2020

Reviewer, Special Emphasis Panel (SEP) the Loan Repayment Program (LRP), National Cancer Institute, 2020

Member, “Planning Grants for Global Research Infrastructure in Non-Communicable Disease,” Special Emphasis Panel, ZCA1 GRB-S (M2), National Institutes of Health, Gaithersburg, MD, April 27–28, 2016.

Member, Review Committee, Spring 2013–14 James & Ester King Research Program, Florida Department of Health, Miami, FL, May 30, 2014

Member, “Reducing Health Disparity Small Business Innovation Research (SBIR) Review Panel,” ZEB OSR-B J1 R, National Institutes of Health, November 9, 2013

Reviewer, C¹⁷ Research Network for Pediatric Oncology, Hematology and Hematopoietic Stem Cell Transplantation Research Grants Program, 2012

Ad Hoc Reviewer, National Institutes of Health, Cancer Biomarkers Study Section, 2011– present

Ad Hoc Reviewer, National Institutes of Health, National Cancer Institute, Subcommittee H (cooperative group review committee), 2009–2010

Chair, Special Emphasis Panel ZH1 CCT-S C3, “Registry and Surveillance System in Hemoglobinopathies (RuSH),” National Heart, Lung, Blood Institute, May 11, 2009

Member, National Institutes of Health, National Cancer Institute, “Reducing Barriers to Symptom Management and Palliative Care” Review Committee, 2005
Reviewer, Program Project Grant “Assessment of Impacts of Childhood and Adolescent Cancer Survivorship,” National Cancer Institute of Canada, 2003 and 2004

Member, San Antonio Life Sciences Institute Executive Committee, University of Texas Health Science Center at San Antonio, 2002–2004.

Member, National Institutes of Health, National Cancer Institute, Small Grants Program for Behavioral Research in Cancer Control, 2002

Reviewer, Special Emphasis Panel (SEP) the Loan Repayment Program (LRP), National Cancer Institute, 2001–2014

Member, Presidential Research Enhancement Funds Review Committee, UTHSCSA, 2001–2004

Chair, Community Clinical Oncology Program (CCOP) Special Emphasis Panel, National Cancer Institute, National Institutes of Health, 2000

Chair, Small Grants Program for Behavioral Research in Cancer Control, National Institutes of Health, National Cancer Institute, 2000

Co-Chair, National Cancer Institute Special Review Committee for the Minority-Based Community Clinical Oncology Program (MB-CCOP), National Institutes of Health, 1999

Member, National Cancer Institute Scientific Review Group Subcommittee E (Cancer Epidemiology, Prevention and Control), Ad Hoc Reviewer, National Institutes of Health, 1999

Co-Chair, National Cancer Institute Special Review Committee for the Community Clinical Oncology Program (CCOP), National Institutes of Health, 1999

Member, Special Review Panel for the National Center for Environmental Statistics, U.S. Environmental Protection Agency, 1997

Member, National Cancer Institute Special Emphasis Panel for the Community Clinical Oncology Program (CCOP), National Institutes of Health, 1995–1998

ACADEMIC PROGRAM REVIEWER:

External Reviewer, University of Texas Medical Branch, Department of Preventive Medicine and Community Health, 2018

External Reviewer, University of Washington, Department of Epidemiology, School of Public Health, 2017

External Reviewer, University of Iowa Department of Epidemiology, College of Public Health, 2017

External Reviewer, University of California San Diego, Department of Family Medicine and Public Health, 2015

External Reviewer, Department of Biostatistics, School of Medicine, University of Kansas Medical Center, Kansas City, KS, 2012–2020

JOURNAL REVIEWER:

Ad Hoc Review, Journal of the National Cancer Institute, 2018 – present
Ad Hoc Reviewer, Cancer Epidemiology, Biomarkers & Prevention, 2016 – 2017
Ad Hoc Reviewer, Journal of Pediatric Hematology and Oncology, 2016 – present
Ad Hoc Reviewer, Sports Medicine, 2016
Ad Hoc Reviewer, Sports Medicine, 2016
Ad Hoc Reviewer, Journal of Investigative Dermatology, 2014
Editorial Board, Journal of Adolescent and Young Adult Oncology, 2010 – present
Editorial Board, Journal of Clinical Oncology, 2006 – 2009
Editorial Advisory Board, Journal for Clinical Research Excellence (Society for Clinical Research Associates), 2008 – present
Regular Reviewer, Pediatric Blood & Cancer, 2001 – 2008
Regular Reviewer, Journal of Clinical Oncology, 2000 – 2006
Regular Reviewer, Cancer, 1997 – 2004
Ad Hoc Reviewer, New England Journal of Medicine, 1997 – 2000
Ad Hoc Reviewer, International Journal of Cancer, 1997 – 2008
Regular Reviewer, Medical and Pediatric Oncology, 1996 – 2000
Ad Hoc Reviewer, Journal of American Public Health, 1994 – 1995
Regular Reviewer, Journal of Pediatric Hematology/Oncology, 1992 – 2001